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 Nanopulse treatment (NPT) is a high-power electric engineering modality that has 
been shown to be an effective local tumor treatment approach in multiple cancer models. 
Our previous studies on the orthotopic 4T1-luc breast cancer model demonstrated that 
NPT ablated local tumors. The treatment consequently conferred protection against a 
second live tumor challenge and minimized spontaneous metastasis. This study aims to 
understand how NPT mounts a potent immune response in a predominantly 
immunosuppressive tumor.  
 NPT changed the local and systemic dynamics of immunosuppressive cells by 
significantly reducing the numbers of regulatory T cells (Tregs), myeloid-derived 
suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) that contribute 
to the dominant immunosuppressive environment in the 4T1-luc mouse breast cancer 
model. The Treg suppression capacity and activation markers, including 4-1BB and 
TGFβ, were diminished post-treatment, and the Treg activation profile shifted from a 
predominantly activated (CD44+CD62L-) to a naïve (CD44-CD62L+) profile. Furthermore, 
we observed an increase in apoptosis among Tregs and TAMs followed by a concomitant 
M1-macrophage polarization of the surviving TAMs. Meanwhile, a continuing rise in the 
effector T cell (Teff) / Treg ratio and among resident memory CD8 T cells hinted at the 
 
 
expansion of antitumor specific cytotoxic T cells. Overall, these findings suggest that NPT 
is a potent tumor microenvironment (TME) modifier that can effectively reverse the 
tumor’s immunosuppressive barrier by decreasing MDSCs, TAMs and functionally 
suppressive Tregs. Thus, the TME modification by NPT confers cytotoxic T cell function 
and immune memory formation contributing to the tumor challenge rejection and 
reduction in metastasis risk. 
 Future studies will investigate the underlying mechanisms of NPT-induced T cell 
immunity by determining the changes it creates among Treg and Teff T cell receptor 
(TCR) clonality in both mice and humans. Control studies on human blood indicated that 
peripheral Tregs are predominantly polyclonal in nature among healthy donors. Overall, 
these findings on NPT-induced immunity can help develop novel immunotherapeutic 
approaches to effectively treat poorly immunogenic cancers, such as breast and 
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APC   Antigen-presenting cells 
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CDR3  Complementarity-determining region 3 
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irAE   Immune-related adverse event 
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MDSC  Myeloid-derived suppressor cell 
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nsEP   Nanosecond electric pulse 





RFA   Radio frequency ablation 
TAA   Tumor-associated antigen 
TAM   Tumor-associated macrophage 
TCR   T cell receptor 
Tconv, Teff   Conventional (or effector) CD4+ T cell 
TIL   Tumor infiltrating lymphocytes  
TME   Tumor microenvironment 
Treg   Regulatory T cell 
Trm   Resident memory T-cells 
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CHAPTER 1  
INTRODUCTION 
1.1 Background on the tumor microenvironment and Tregs 
 The tumor microenvironment (TME) is a complex network of tumor cells, T cells, 
B cells, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages 
(TAMs), tumor-associated neutrophils, natural killer (NK) cells, dendritic cells (DCs), 
cancer-associated fibroblasts (CAFs), vascular endothelial cells, adipocytes, pericytes, 
as well as extracellular matrix (ie. collagen, fibronectin, hyaluronan, laminin) and signaling 
components (ie. cytokines, chemokines, exosomes). Among the cellular components, 
immunosuppressive cells, such as regulatory T cells (Tregs), MDSCs and TAMs play a 
critical role in suppressing antitumor immunity and promoting tumor growth (1,2).  
1.1.1 Tregs 
 Tregs represent a small subset (5-10%) of the total circulating CD4+ T cell 
population (3) and have an essential role in maintaining immune homeostasis and 
preventing autoimmunity (4).  Their expression of CD4 and CD25 cell surface antigens 
and the Foxp3 transcription factor distinguishes them from the effector (or conventional) 
CD4+ T cells (Teff) (5). Immune dysregulation polyendocrinopathy, enteropathy, X-linked 
(IPEX) is an uncontrolled systemic autoimmune condition that occurs in the absence of 
Tregs or when the Foxp3 locus is disrupted. This condition is lethal to patients and 
requires a bone marrow transplant (6). A ‘scurfy mutation’ in mice is the absence of Foxp3 
expression through genetic deletion, which similarly manifests in autoimmune 





  While Tregs represent around 10% of the total CD4+ T cell population in healthy 
peripheral organs, their proportions are increased in the TME where they can constitute 
30-50% of the total CD4+ population (7,8). These TME Tregs are found to be functionally 
immunosuppressive via in vitro suppression assays, which are the ‘gold standard’ for 
confirming bona fide functional Tregs in tumors  by measuring how intensely their 
presence suppresses effector T cell proliferation (9). 
 Treg presence in the TME diminishes antitumor immunity, and their 
immunosuppressive function is a dominant mechanism in the tumor cell evasion of 
immune responses (6,7). CD4+CD25+ Tregs in the tumor infiltrating lymphocytes (TIL) 
population isolated from cancer patients suppress autologous effector T cells in a cell-
contact manner (PD-1, CTLA-4, 4-1BB) and by producing immunosuppressive cytokines 
TGFβ and IL-10 (4-6). These intratumoral Tregs mediate stronger suppression in 
comparison to Tregs isolated from peripheral blood mononuclear cells (PBMCs) (10,11). 
High frequencies of Tregs in the TME, affected lymph nodes and/or in the peripheral blood 
have been reported in a variety of human cancers (12,13), including lung cancer (14), 
liver cancer (15), head and neck cancer (16), lymphoma (17), breast cancer (18-20), 
ovarian cancer (21,22) and melanoma (5,6,23).  
 In multiple tumor types, including breast cancer, Treg presence in the TME 
worsens the prognosis and reduces patient survival (20,21,23,24), and a high intratumoral 
CD8+ effector T cell to Treg ratio is associated with a favorable prognosis and better 
survival (8,13,23-26). Tregs’ ability to suppress not only spontaneous T cell response, but 
also to hamper immunotherapeutic interventions aimed at inducing antitumor responses, 






MDSCs are a heterogeneous population of myeloid cells that can be identified by 
their expression of the Gr-1 and CD11b cell surface markers (27,28). MDSCs promote 
tumor progression via several mechanisms including immune suppression (29), 
particularly of T cells. MDSC immunosuppressive mechanisms include (27): a) ARG1-
dependent depletion of L-arginine (30) and L-cysteine sequestration (31). This 
mechanism depletes CD3ζ chain (of the TCR complex, see Fig. 1) amino acids required 
for antigen-mediated T cell activation and proliferation (27). b) Disruption of T cell viability 
and trafficking via Galectin 9 and ADAM17 molecules expressed on MDSCs (32,33). 
Galectin 9 binds to TIM3 on lymphocytes to induce T cell apoptosis (33), while ADAM17 
decreases the lymphocyte-expressed L-selectin and disrupts T cell recruitment in LNs 
(27,32,33). c) Treg activation and expansion with concomitant Tconv suppression (34), a 
process associated with the CD40-CD40L interaction, whereby CD40L is T cell-
expressed and CD40 is MDSC-expressed. MDSC IL-10 and TGFβ cytokine secretion and 
PD-L1 expression further contribute to the above process (27,35,36). d) Generation of 
oxidative stress, which nitrates TCRs and limits their response to the MHC-antigen 
complex (27,37,38). 
1.1.3 TAMs 
TAMs can be classified as cytotoxic antitumor M1 macrophages (CD206- with high 
MHC-II expression) and immunosuppressive tumor-promoting M2 macrophages (CD206+ 
with low MHC-II expression) (36,39,40). TAMs in breast cancer have been demonstrated 
to have an M2 phenotype in gene expression studies. (36,41-43). TAM polarization 





breast cancer (44) and in brain metastasis in breast cancer (36,45). TAMs in the 4T1 
murine mammary cancer models and the MDA-MB-231 human breast cancer model 
demonstrate MHC-II downregulation (36,46). The presence of M1 TAMs in breast cancer, 
on the other hand, is associated with decreased cancer invasion and metastasis, and 
increased cancer cell apoptosis (36,47,48). 
1.2 T cell antigen-specificity in cancer and its significance in current therapies 
1.2.1 Tumor-infiltrating lymphocytes 
The host immune system generally recognizes tumor cells as non-self and may 
initiate a cellular (Fig. 1) and/or humoral immune response to eliminate them (49). Human 
and animal tumors are infiltrated by lymphocytes known as tumor-infiltrating lymphocytes 
(TILs), primarily composed of CD4+ and CD8+ T cells, that may represent the host immune 
response to the tumor (49-51). TILs represent the immune response of the host to the 
tumor, and their presence in certain tumors has been associated with improved prognosis 
and higher survival (9,49-53). These TILs recognize autologous tumor cells in an antigen-
specific manner (49).  
1.2.2 Tumor vaccines and adoptive cell therapy  
Tumor vaccine strategies initially relied on targeting tumor associated antigens 
(TAAs), such as HER2, MART-1, MUC1, and NY-ESO-1, which are self-antigens 
common to both the tumor and normal cells (54). Vaccines generated to the above TAAs 
conferred some degree of response, however, side effects were common (54). Current 
approaches are more focused on targeting neoantigens, a subset of tumor-specific 





mutations and, compared to TAAs, are more immunogenic as they are not expressed on 
normal tissue cells (55). Successful designs and applications of neoantigen vaccines in 
breast cancer and other cancers have been expanding rapidly (54,56). A current clinical 
trial (NCT03412877) at the National Cancer Institute actively recruits patients with 
incurable or metastatic cancers, including breast cancer, with the objective of treating 
them with neoantigen-reactive TCRs transduced into autologous peripheral lymphocytes 
(54,57).   
Adoptive cell transfer of antigen-specific T cells is another method of “harnessing 
the immune system to combat cancer (58)”. In adoptive cell transfer, antigen-specific T 
cells are isolated from cancer patients, expanded ex vivo then re-admitted to the patient 
in activated form to target and eliminate tumor cells (58). A clinical trial (NCT03970382) 
proposed by PACT Pharma Inc. utilizes autologous T cells engineered to express 
autologous TCRs reactive to unique patient-specific neoantigens (54). 
 
Figure 1.  
Antigen-mediated T cell stimulation. The α and β chains of the TCR recognize the MHC-bound antigen on 
an APC, and the CD4 (or CD8) co-receptor molecule interacts with the MHC. These events (1st signal) 





Figure 1. (Continued.) Co-stimulation (2nd signal) is then delivered via the CD28-CD80/86 interaction. 
TCR α and β chains each have a constant (C) and variable (V) region. This figure was designed using 
Microsoft Word Office 365. 
1.3 Targeting Tregs in cancer 
In tumor immunity, Tregs become activated in tumor tissues and tumor-draining 
lymph nodes (dLN) by antigen recognition (59). These Tregs exhibit significant 
proliferative potential in vivo (9,59), and suppress effector T cell proliferation and cytokine 
secretion (59). In mouse studies, antigen-specific Tregs exhibit superior suppressive 
capacities when compared to non-antigen-specific Tregs (60).  In order to understand 
how Tregs accumulate in tumors, a recent study demonstrated that the intratumoral Tregs 
and Tconv had distinct TCR repertoires (61). 
Their findings suggested that circulating Tregs selectively migrate into the tumor 
where they are activated and undergo clonal expansion in an antigen-specific manner 
rather than in a non-specific polyclonal manner (61). The most dominant TCRs from these 
intratumoral Tregs had tumor- and neoantigen-specific reactivity (61).  
Strategies aimed at evoking antitumor immunity may focus on better controlling 
the Treg-Tconv balance by tipping it away from the immunosuppressive Treg activity and 
towards an antitumor effector T cell response (59).  
1.3.1 Immune checkpoint inhibitors 
In addition to the TCR-antigen/MHC interaction (Fig. 1), antigen-mediated T cell 
activation and expansion require co-stimulatory cell surface signaling (62). This signaling 
process involves an interaction between co-stimulatory molecules, such as CD28, 





cells can express cell surface co-inhibitory receptors, such as cytotoxic T-lymphocyte-
associated antigen-4 (CTLA-4), which compete against CD28 and attenuate the T cell 
response (35).  
Such immune checkpoints are required to prevent T cell autoreactivity and 
maintain immune homeostasis under physiological conditions (62). Tumor cells 
themselves may express inhibitory signaling molecules, such as CTLA-4, and influence 
the immune checkpoint pathway to obstruct the antitumor T cell response (35,62). The 
inhibitory interaction of the programmed cell death-1 (PD-1) receptor on T cells with the 
programmed cell death ligand 1/2 (PD-L1, PD-L2) expressed on tumor cells is another 
example of checkpoint pathway manipulation by the tumor (35,62). Tregs that are 
abundant in the TME also express immune checkpoint molecules, including PD-1, CTLA-
4, that contribute to the contact-mediated immunosuppression. 
Immune checkpoint inhibitors were developed to target these tumor-hijacked 
pathways with the hope of restoring normal T cell immunosurveillance and tumor 
clearance (6,35). Such immunotherapeutic approaches gained growing interest in 2010 
when Ipilimumab, now an FDA-approved antibody targeting CTLA-4, demonstrated a 
20% improvement in the overall survival of patients with metastatic melanoma (6,63,64). 
Nivolumab, an antibody targeting PD-1, was approved in 2014 after showing a 40% 
objective response rate in melanoma patients (6,65). And in 2018, the Nobel Prize in 
Medicine was awarded for the checkpoint inhibitor immunotherapy (35,66). Unfortunately, 
the presence of suppressor cells such as Tregs, MDSCs and TAMs, coupled with few 
pre-existing TILs, in low immunogenic tumors prevents widespread applicability of 





Ipilimumab and tremelimumab, both anti-CTLA therapies, were tested in breast 
cancer with limited efficacy (62,67,68). Triple Negative Breast Cancer (TNBC) is an 
example of a genetically unstable malignancy that demonstrates a limited response to 
checkpoint inhibitor immunotherapy (35,69,70). Significant variations in patient treatment 
responses are even seen within the same cancer type, such as in advanced ER+ breast 
cancer (35,71,72). Furthermore, these systemic therapies carry the risk of toxic and 
severe adverse effects, including severe immune-related adverse events (irAEs)  (73,74).  
1.3.2 Manipulating Treg chemokine-mediated recruitment to the tumor 
 Chemokine ligands (CCL, CXCL) secreted by the TME promote the recruitment of 
chemokine receptor-expressing (CCR, CXCR) Tregs in various tumor types (75,76). 
CCL22 is reported to attract CCR4+ Tregs to the TME in breast cancer (75,76). Other 
chemokines and their corresponding receptor in various types of tumors include CCR8 
(77) and CCR5-CCL5 in pancreatic cancer (75,78) , and CCR4-CCL22, CCR10-CCL28, 
and CXCR4-CXCL12 in ovarian cancer (75,79).  
 Chemotaxis-blocking antibodies or small molecules have been used to reduce 
Treg accumulation in tumors (75), which in turn, increases antitumor immunity (80). CCR4 
is a key marker used in the specific depletion of Tregs. The use of anti-CCR4 therapy has 
been shown to simultaneously deplete Tregs and increase CD4+ and CD8+ T cells (and 
their activation (79,81). Activated human Tregs have a high CCR4 expression, unlike 
naïve Tregs or most effector T cells (80,82). Mogamulizumab, an anti-CCR4 mAb has 
been implemented in clinical trials to evoke antitumor immunity by selectively depleting 
activated Tregs (80,83). The drug was shown to significantly reduce activated Treg cells 





1.3.3 Treg reprogramming 
While some studies show the pro-tumorigenic effects of Th17 cells, recent 
advances in immunotherapy have demonstrated strong antitumor effects and clinical 
benefits in tipping the Treg/Th17 axis towards a Th17 profile (84). Though the Th17 
antitumor mechanism is not yet clear, studies suggest Th17 cells may exert their 
mechanism through direct tumor lysis or CD8 cell synergism (84).  Furthermore, Th17 
cells have demonstrated apoptosis and activation-induced cell death (AICD) resistance 
and a strong ability to retain antitumor efficacy when compared to Th1 cells (84). 
1.3.4 Manipulating antigen-specific Tregs in cancer 
Analyzing the in vivo Treg TCR distribution is critical to determine Treg antigen-
specificity in cancer (and autoimmune disease) patients given Tregs’ ability to obstruct 
not only spontaneous immunity, but also immunotherapeutic interventions. Many tumor 
antigen-based vaccines intended to bolster antigen-specific immunity have been 
demonstrated to counterproductively elicit Treg immunosuppressive response (85). In a 
study on mice, an immunization course lead to in vivo expansion of Tregs that were 
demonstrated to efficiently suppress the expansion and function of activated T cells (85). 
In another study, antigen-specific Tregs were shown to be induced after vaccinating 
melanoma patients with cancer-testis antigen NY-ESO-1 (86). Following patient 
vaccination, tumor digests analyzed by flow cytometry –prior to culture– revealed Tregs 
constituted 41% of the total CD4+ population in the tumor site, a value 10-fold greater 
than Treg representation in blood (86). TILs were then cultured in IL-2 and stimulated with 
antigenic peptides NY-ESO-185-102 and NY-ESO-1115-132 (86). No significant response was 





Tregs, within the expanded TIL population, exhibited antigen-specific response 
determined by CD3 downregulation (86). The Treg response to this peptide was ~4-fold 
greater than that of effector T cells, with more than 40% of Tregs exhibiting CD3 
downregulation (86). 
Determining the tumor antigen recognition patterns of Tregs (60,87) will therefore 
permit new considerations to be taken into account when selecting for the optimal tumor 
antigen for vaccine development (49). It will be critical to select for tumor antigen peptides 
that stimulate an exclusively effector T cell, without inadvertently inducing a concomitant 
Treg response (85). More recently, the Treg and Tconv TCR repertoires have been found 
to be distinct with minimal overlap (61), and tumor vaccine strategies now favor targeting 
neoantigens over TAAs (54). These recent findings and advances have positive 
implications for improving the efficacy of tumor vaccine designs.  
1.4 Nanopulse treatment and other local cancer therapies  
 Targeting intratumoral Tregs locally, whether by downregulating activated Tregs 
or inducing Treg cell death, may help reverse the imbalance between 
immunosuppression and immunostimulation, and avoid toxic systemic effects (88). 
However, this idea has not been studied as extensively as systemic approaches. 
1.4.1 Local tumor ablation therapies 
 Local tumor ablation therapies have the potential to treat tumors with fewer severe 
side effects. Irreversible electroporation (IRE), electrochemotherapy, cryoablation, laser 
ablation, radio frequency ablation (RFA), and radiotherapy (RT) are some examples of 





effective antitumor immunity, or they require additional treatment with immune-
modulators such as the addition of immune checkpoint inhibitors (PD-1 inhibition) or 
antitumor cytokines (IL-15) (89). Radiotherapy combination treatments show promising 
antitumor response (90). However, radiotherapy alone has been shown to increase Tregs 
in the TME, and it requires the combined use of immunomodulators and other systemic 
therapies in order to reduce Treg number and effectively treat tumors (90). 
1.4.2 Nanopulse treatment of tumors 
 Nanopulse Treatment (NPT), also known as Nanopulse Stimulation (NPS) or 
nanosecond electric pulses/pulsed electric fields (nsEPs/nsPEFs), is a high-power 
electric engineering technology that generates an ultra-short (pulse durations 1 to 999 
nanosecond) and high intensity (electric fields 5 to 68 kV/cm)  electrical pulses to ablate 
tumors in multiple animal models, including mouse melanoma, breast cancer, pancreatic 
cancer, lung squamous cell carcinoma, rat hepatocellular carcinoma, xenograft 
pancreatic cancer, etc. (89,91,92). Unlike many systemic immunotherapies and 
chemotherapy, which are often long-term  treatments associated with many serious side 
effects, NPT is minimally invasive and only requires short (5-7 minute) intervals when the 
tumor is covered within the electrode array (91).  
1.4.3 Investigating the impact of NPT on Tregs and other immunosuppressive 
cells in breast cancer 
 In our previous study, NPT ablated primary breast tumors in a poorly immunogenic 
breast cancer model (orthotopic mouse 4T1-luc). The treatment resulted in a strong 
vaccine effect that rejected 100% (11/11) of live secondary tumor challenges and 





tumor model is a very aggressive and spontaneously metastatic malignancy with 
abundant immune suppressive cells, including Tregs, TAMs and MDSCs in the TME 
(93,94). Successful treatments of the above model and the Pan02 pancreatic cancer 
model also showed a reduction in intratumoral and blood Tregs several days after NPT 
(89).   
  However, we still do not know the underlying mechanism of the NPT impact on 
Tregs and other immunosuppressive cells. Investigating the NPT-associated changes in 
Treg, MDSC and TAM dynamics may further clarify the treatment’s antitumor effect. 
Elucidating the mechanisms impacted by NPT may help develop novel 
immunotherapeutic approaches to effectively treat poorly immunogenic cancers like 
breast cancer. 
 Tumors contain Treg infiltrates that have accumulated and become activated to 
create a barrier to the tumor-eliminating immune response. I hypothesize that NPT of 
mouse breast cancer induces Treg cell death and reduces their functional capacity to 
diminish the immunosuppressive barriers. To test my hypothesis, I characterized NPT-
induced local and systemic changes in immune profiles, particularly among Tregs.  
 In this study, I showed that NPT altered Treg phenotypic dynamics and reduced 
their suppressive capacity by diminishing activated Tregs and inducing Treg cell death, 
thus releasing a major immunosuppressive brake. MDSCs and TAMs were also 
dramatically reduced in the TME but exhibited distinct dynamics and cell death changes 
following NPT. Conventional CD4 T cells (Tconv) were more resilient to NPT-induced 





cells (Trm) significantly increased over time post-NPT. An investigation of the Treg 
signaling and functional changes post-treatment demonstrated that NPT is quite adept at 








2.1 Mouse Nanopulse treatment studies 
2.1.1 Mice 
 Female Balb/c mice (8–10 weeks of age) were purchased from Jackson 
Laboratory. The mice were housed and maintained at the ODU AAALAC approved animal 
facility.  All animal procedures in this study were approved by the IACUC (protocol 18-
008) at Old Dominion University. 
2.1.2 In vivo Nanopulse treatment 
 Tumors were initiated by subcutaneously injecting female Balb/c mice with 1x106 
4T1-luc cells in 50 μL DPBS (Life Technologies) in the left posterior mammary fat pad. 
NPT was performed on Day 11 following tumor inoculation when average tumor sizes 
were 6-8 mm or 60-100 mm3. Prior to treatment, hair was thoroughly removed. The tumor 
mass and electrodes were covered with ultrasound gel to maintain uninterrupted tumor-
electrode contact and prevent air accumulation that creates electrical breakdowns. I 
delivered the high‐voltage pulses (Fig. 2) making sure only the tumor mass receives 
treatment. Nanosecond electric pulses were delivered to the tumor tissue using a two‐
plate pinch electrode with an 8 mm diameter.  The NPT parameters were: pulse duration 
100 ns with fast rise-fall times, pulse frequency 3 Hz, applied electric field 50 kV/cm and 
a pulse number of 1000 pulses. Depending on the experimental design, mice were 






Figure 2.  
Nanopulse treatment pulser setup. A-C, Components of the NPT pulser include the oscilloscope (A), power 
supplier (B) and fixed 100 ns Nanopulser (C). High-power ultra-short pulses are delivered to the mouse 
breast tumor via a pinch electrode covering the entire tumor mass.  
 
 
Figure 3.  
In vivo NPT experimental design. 1x106 4T1-luc cells were injected subcutaneously into the posterior part 





Figure 3. (Continued.) The remaining mice underwent NPT (100 ns pulses, 50 kV/cm, 1-3 Hz, 1000 
pulses) on Day 11 following tumor inoculation. The treated mice were euthanized 4 hours, 8 hours (for local 
tissues only), and on Day 1, Day 3, and Day 7 post-NPT. Their tumor tissues, tumor-draining lymph nodes 
(dLN), blood and spleens were harvested. Control tissues were obtained from mice with untreated tumors. 
Single cell suspensions from each tissue were prepared. 
 
2.1.3 Preparation for single cell suspensions  
 The primary solid tumor (Fig. 4), dLN, blood and spleen were collected and 
prepared into single cell suspensions for downstream analysis. Spleen and dLN were 
gently mashed through a 70 µm cell strainer into a conical tube. The dissociated spleen 
and the blood underwent RBC lysis to make cell suspensions for further analysis. For 
solid tumor processing, fat and other surrounding tissues were removed and the tumor 
samples were washed with RPMI 1640 (Life Technologies) and cut into 1-5 mm3 pieces. 
The cut pieces were then dissociated with the Miltenyi Biotec tumor dissociation kit and 
the Gentlemacs Octo-dissociator (with heater) using the tough tumor dissociation 
protocol. The digest was then passed through a 70 µm cell strainer to remove clumps. 
Tumor single cell suspensions then underwent magnetic bead based CD45 TIL isolation 







Figure 4.  
Changes in 4T1-luc solid tumor morphology following NPT. Breast cancer tumors were surgically resected 
on post-inoculation Day 11 from tumor-bearing mice (control) and from NPT-mice at 4 hours, Day 1, Day 
3, Day 7 post-treatment timepoints. 
 
2.1.4 Flow Cytometry 
 To perform cell surface staining, cells were washed with FACS buffer then 
incubated with anti-FcR (TruStain FcX™ PLUS, Biolegend) for 10 min on ice to block 
unspecific binding of antibodies. The following fluorochrome-labeled antibodies were 
used for Treg, MDSC and TAM labelling: CD4 FITC, CD8 APC/Cy7, CD3 BV510, CD25 
APC, CTLA-4 PerCP/Cy5.5, PD-1 PE/Cy7, CCR4 BV421, 4-1BB APC, TGFβ BV421, 
CD45 Pacific Blue, CD11b PE, Gr-1 PE/Cy7, F4/80 FITC, and CD86 APC/Cy7. All cell 
surface antibodies were purchased from Biolegend. 
 For intracellular and intranuclear staining, single cell suspensions were first 
labelled with cell surface antibodies, followed by fixation and permeabilization using the 
Foxp3 transcription factor buffer set (Thermofisher Scientific). Permeabilized cells were 
then labelled with Foxp3 PE, Helios PerCP/Cy5.5, IL-17 PE/Cy7, RORγt PerCP-Cy5.5 
and/or IFN-γ PerCP-Cy5.5 primary antibodies (Thermofisher Scientific). Cytokine staining 
using the above buffer and cytokine antibodies from Thermofisher Scientific was verified 








with the company’s in-house data as well as our own experimental data. This technique 
allowed us to co-stain for Foxp3, RORγt, IL-17 and IFN-γ in the same panel to investigate 
for reprogramming.  
 For cell apoptosis studies, cells were labelled with Zombie NIR and Annexin V 
(Biolegend). Due to the sensitivity of the phosphatidylserine bond (for Annexin V binding) 
to the fixation/permeabilization process (for Foxp3 analysis), I did not incorporate Annexin 
V and Foxp3 co-staining in the same panel. To perform the cell apoptosis studies, freshly 
obtained single cell suspensions were first labelled with Zombie NIR using a serum-free 
PBS buffer. Cells were then washed with FACS buffer to perform cell surface staining. 
The labelled cells were then washed and resuspended in Annexin V binding buffer, 
stained with Annexin V, and immediately acquired by flow cytometry.  
 Stained cells were analyzed on a MACSQuant 10 Analyzer, BD FACS Calibur and 
BD FACS Canto II at Old Dominion University and Eastern Virginia Medical School. The 







Figure 5.  
CD25+Foxp3+ Treg gating strategy. A-E, Summary flow plots representing the Treg gating strategy. A, 
Single cell suspensions from the dLN of 4t1-luc tumor-bearing mice were gated on the forward scatter 
(FSC) vs side scatter (SSC) dot plot to select lymphocytes. B, Lymphocytes were then gated on the FSC-
Height vs FSC axis to eliminate doublets. C and D, CD3 cells were selected (C) and gated on the CD4 vs 
CD8 axis to separate CD4-single positive and CD8-single positive T cells (D). E, CD4-single positive T cells 
were then gated on the CD25 vs Foxp3 axis to select CD25+Foxp3+ Tregs. 
 







Figure 6.  
MDSC and TAM gating strategy. A-G, Summary flow plots representing the MDSC gating strategy. A, 
Single cell suspensions from surgically resected tumors of 4t1-luc tumor-bearing mice were gated on the 
forward scatter (FSC) vs side scatter (SSC) dot plot to select lymphocytes. B, Lymphocytes were then 
gated on the FSC-Height vs FSC axis to eliminate doublets. C, CD45+ CD11b+ leukocytes were selected. 
D, CD3+ cells were excluded (negative selected). E, The remaining CD3- T cells were then gated on the 
Gr-1 vs F4/80 axis to separate MDSCs and TAMs. F, Gr-1+F4/80- cells were subgated on the Gr-1 vs 
CD11b axis to identify Gr-1+CD11b+ MDSCs. G, F4/80+Gr-1- cells were subgated on the Gr-1 vs CD11b 
axis to identify F4/80+CD11b+ TAMs. 
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2.1.5 In vitro Treg suppression assay 
 CD4+CD25+ Tregs were isolated from dLN of tumor-bearing mice and NPT-treated 
mice on post-treatment Day 2. To obtain a sufficient number of Tregs, dLN from 2-3 mice 
were pooled together for each group. Spleen-derived CD8 responder (Tresp) cells were 
isolated from naïve mice by negative selection using magnetic beads (Stemcell 
Technologies). Purified responder cells were labelled with 5 µM CFSE (ThermoFisher 
Scientific) and plated in a 96-well round-bottom plate at a density of 4 × 104 responder 
cells per well. CD4+CD25+ Tregs were co-incubated with CFSE-labelled responder cells 
at the Treg:Tresp ratios 1:1, 1:2 and 1:4. The plates were incubated at 37°C with 5% CO2 
for 60 hours in the presence of CD3/CD28 activation beads (ThermoFisher Scientific). 
Responder cell proliferation was quantified by flow cytometry based on the dilution of the 
CFSE dye. Treg suppression was calculated in the following manner: %Suppression = 
[1-(%proliferating Tresp at Treg:Tresp ratio / %proliferating Tresp-only cells)] x100.  
2.1.6 Statistical Analysis 
P-values were generated using one-way ANOVA with a minimum of n=3. P-values 
<0.05 were considered to be statistically significant. 
2.2 Human TCR studies 
2.2.1 Isolation of mononuclear cells from human peripheral blood using density 
gradient centrifugation 
 100 mL of freshly drawn blood was shipped on ice overnight and sample 
processing was initiated immediately upon arrival. 50 mL of blood was diluted 2x by 





150 mL blood-buffer solution was divided equally among five conical tubes for density 
gradient centrifugation: 
 15 mL of Ficoll-Paque (GE Healthcare) was added to each (of five) 50 mL conical 
tubes. 30 mL (from a total of 150 mL) of diluted blood-buffer suspension was carefully 
layered, drop-by-drop, over the Ficoll layer, making sure not to disrupt the Ficoll cushion 
in the process.  
 The conical tubes were centrifuged at 400xg for 35 minutes at 18°C in a swinging 
bucket rotor. Brakes were disabled; acceleration set to low. The plasma layer was 
aspirated leaving the mononuclear cell Buffy coat (lymphocytes, monocytes, 
thrombocytes) undisturbed at the interphase. The buffy coat layers were then extracted 
and combined in a new 50 mL conical tube. Up to 5 mL of the buffy coat content was 
placed in the new tube (to allow for 10X dilution with PBS buffer).  
 Each conical tube was then topped with fresh PBS buffer (for a total of 50 mL; 10x 
dilution) and centrifuged at 300xg for 10 minutes at 18°C. Brakes were enabled; normal 
acceleration. The cell pellet was then washed twice with PBS at 200xg for 10 minutes to 
thoroughly remove platelets that can interfere with the purification process. After the final 
wash, the cell pellet was resuspended in 15 mL Microbead buffer (Calcium-free, 
Magnesium-free PBS supplemented with 0.5% FBS and 2 mM EDTA) to prepare for the 
CD4+ cell microbead enrichment step.  
2.2.2 CD4+ T cell microbead-based enrichment 
 To perform CD4+ T cell enrichment, microbead-bound antibodies (Miltenyi Biotec) 





were used to label non-CD4+ peripheral blood cells. These antibody-labelled non-CD4 
peripheral blood cells were then run through the microbead column, causing them to bind, 
while the unlabeled CD4+ cell-enriched effluent was collected and prepared for automated 
cell sorting. The non-CD4+ cells bound to the column were discarded.  
2.2.3 Fluorescence-antibody tagging of enriched CD4+ T cells 
 A cell count was performed, and the enriched CD4+ cells were washed twice with 
ice cold PBS at 300xg for 7 minutes at 4°C. After the final wash, the pellet was vortexed 
and resuspended in the ~50 µL leftover buffer.  For FACS sorting, the cells were labelled 
using the following dyes: eBioscience CD4 eFluor 450, CD25 APC and CD127 PE. 35 µL 
of each dye was added to the cells. The tube was incubated for 30 minutes on ice, in the 
dark.  
 Five tubes were prepared for sorting: Tube 1 contained the enriched CD4+ cells 
that were labeled with all three dyes. To setup dye controls, three separate single stain 
PBMC controls were prepared: Tube 2 CD4 eFluor 450, Tube 3 CD4 APC, Tube 4 CD4 
PE. An unstained PBMC control (Tube 5) was also prepared. Following incubation, cells 
were washed twice in PBS, filtered, and placed in a 15 mL FBS pre-coated polypropylene 
tube to prepare for cell sorting. 
2.2.4 Regulatory T cell isolation using multicolor FACS sorting 
The following gating strategy was setup to isolate CD4+CD25+CD127lo Tregs:  
1) FSC-A vs SSC-A gate to identify live lymphocytes 
2) FSC-A vs FSC-Peak gating to exclude doublets 





4) The CD4+ T cell subset was then gated for CD25+ and CD127lo Tregs 
 Cell sorting was performed to obtain the CD4+CD25+CD127lo pure Treg population 
(positive faction). A post-sort FACS purity analysis was then performed on a fraction 
(>20,000 cells) of the obtained Tregs. A negative fraction containing non-Treg CD4+ T 
cells was also obtained and analyzed post sorting.   
2.2.5 RNA Isolation 
 Both, the purified Treg population and the non-Treg CD4+ T cells, were 
immediately resuspended in Trizol solution (Life Technologies) and placed in -80°C for 
RNA precipitation.    
2.2.6 cDNA synthesis 
 RNA was extracted and purified using the PureLink Mini Kit (Life technologies). 
RNA was then reverse transcribed using the Superscript III RT kit (Life Technologies). 
The reverse transcribed cDNA product was divided into three batches for the following 
downstream applications. Batch 1: analysis of Treg FOXP3 expression. Batch 2: 
amplification of alpha-chain Treg TCR. Batch 3: amplification of beta-chain Treg TCR.  
2.2.7 PCR amplifications 
2.2.7.1 Semi-quantitative PCR analysis of FOXP3 expression among the purified 
Treg population  
 To assess FOXP3 expression in the purified CD4+CD25+CD127lo cells, cDNA 
(from Batch 1) was used to set up a PCR reaction and assess the expression of actin 
(housekeeping gene), CD4 and FOXP3. A similar PCR reaction was setup using the non-





2.2.7.2 Amplification of Treg TCR transcripts using two rounds of nested family-
specific PCRs 
The remaining reverse transcribed Treg cDNA products were used for two rounds of TCR 
chain PCR amplifications.   
2.2.7.2a First PCR reaction 
 To amplify each of the 32 α-chain (Batch 2 cDNA) TCR transcript families, 32 PCR 
reactions were prepared, each containing the hCα3 primer 
(5`CTGGATTTAGGTCTCTCAGCTGGTAC3`) as the 3` Constant (C) region primer, and 
one of the thirty-two 5` Variable (V) region α-chain family primers (detailed in Xu et al. 
2003) (95). 
 A similar process was employed to amplify each of the 24 β-chain (Batch 3 cDNA) 
TCR transcript families using the hCβ3 (5`CAGGCAGTATCTGGAGTCATTGA3`) as the 
3` primer C-region primer and each of twenty-four 5` V-region β-chain family primers 
(detailed in Sakkas et al. 2002) (96). 
2.2.7.2b Second PCR reaction  
 The amplified products from the first PCR reaction were used to perform a second 
nested PCR reaction using the hCα1 (GTTGCTCCAGGCCACAGCACTG) primer to 
amplify the 3` C region and each of the family specific α-chain primers to amplify the 5` V 
region. For the beta-chain, the hCβ1 (CAGGCAGTATCTGGAGTCATTG) primer was 
used for the 3` C region, along with each of the 24 β-chain family primers to amplify the 





2.2.8 Cloning and sequencing 
Amplified samples were then separated by base pair size using agarose gel 
electrophoresis. The gel bands were visualized using ethidium bromide under UV light, 
followed by excision of the bands containing the desired amplified DNA sequences. Next 
the Purelink Quick Gel Extraction Kit (Invitrogen) was used to purify and recover DNA 
fragments from the agarose gel bands. The purified PCR product was then ligated into 
the pCR 2.1-TOPO vector (Invitrogen TOPO TA Cloning kit). Ligated plasmid vector 
containing our desired PCR insert was then transformed into One Shot chemically 
competent E. coli cells (Invitrogen) via heat-shock, followed by a 1 hour incubation of the 
transformed cells in SOC medium on a shaker at 37°C.  
E. coli doubling time is 20 minutes under ideal conditions (97); however, the heat 
shock stress should prevent E. coli from duplicating during this 1 hour incubation period. 
Though unlikely, duplication may occur before plating, resulting in two E. coli cell colonies 
carrying the same insert. The result would be 2 identical CDR3 sequences that have 
originated from premature bacterial doubling rather than from in vivo T cell clonal 
expansion. 
After the 1 hour incubation period, the E. coli bacteria were spread on agar plates 
containing X-Gal and ampicillin, then incubated at 37°C overnight. The TOPO vector 
containing an ampicillin resistance gene confers ampicillin antibiotic resistance upon, and 
allows growth of, successfully transformed E. coli cells. The TOPO vector also contains 
the lacZa gene at the insertion site for the PCR products. The lacZa gene encodes β-
galactosidase enzyme, which breaks down X-Gal in the culture plate to create blue 





disrupt the lacZa gene, thus creating white colonies. Following overnight incubation at 
37°C, blue/white screening was performed to identify and pick successfully transformed 
white E. coli colonies containing the PCR product.  
Picked colonies were cultured in separate Falcon tubes containing Luria-Bertani 
broth suplemented with ampicillin. The tubes were incubated overnight at 37°C to allow 
for bacterial multiplication and cloning of the inserted PCR product. Next, the plasmid was 
prepared using the Promega Wizard Plus Minipreps DNA Purification System. E. coli cells 
were lysed, and the plasmids were isolated, purified and stored in nuclease-free water.  
The isolated plasmids containing the amplified TCR transcripts were then prepared 
for sequencing. Dideoxy chain termination sequencing PCR using BigDye Terminator 
v3.1 Cycle Sequencing kit was carried out. The sequencing PCR products were purified 
using microspin columns followed by vacuum drying and resuspension in Hi-Di 
formamide. The resuspended products were loaded onto a 96-well plate and TCR 
transcripts were read by an automated sequence analyzer. The manufacturer’s software 
provided raw nucleotide sequence data, which were analyzed using the IMGT online 
software (imgt.org). 
V(D)J regions were analyzed to determine the presence of CDR3 nucleotide 
sequences for each of the α- and β- chain TCR transcripts expressed on the Tregs. The 
corresponding amino acid sequences for each TCR transcript were derived through the 
ExPASy proteomics website (expasy.org). Treg TCR transcript sequences were analyzed 








3.1 Overturning the immunosuppressor cell dominance in the TME following NPT 
3.1.1 NPT-induced shift from a Treg- to a Tconv-dominant environment  
 I evaluated Treg prevalence among CD4 T cells in systemic and local tissues (Fig. 
7), including the blood (Fig. 7A and B), spleen (Fig. 7C), dLN (Fig. 7D and E), and tumor 
(Fig. 7F and G) tissues. In untreated mice, I found the Treg percentage among CD4 T 
cells was 18.6% in blood (Fig. 7B), 23.8% in spleen (Fig. 7C), 20.6% in dLN (Fig. 7D), 
and 49.5% in tumor tissues (Fig. 7F). After 4T1-luc tumor-bearing mice were treated with 
100 ns NPT, I observed a significant and sustained drop in this Treg prevalence. Tregs 
were noted to decrease post-treatment by 52.1% in the tumor (4 hour) (Fig. 7F), 42.2% 
in the dLN (Day 3) (Fig. 7D), 52.3% in the blood (Day 3) (Fig. 7B) and 19.7% in the spleen 
(Day 7) (Fig. 7C).   
 Total TIL numbers were found to decrease rapidly following treatment (Fig. 8A). 
Following NPT, the Treg cell count underwent a 4.4-fold reduction by 4 hours and an 8.1-
fold reduction by Day 3 from its untreated intratumoral baseline (Fig. 7G). Tconv, in 
contrast, only experienced a 1.4-fold reduction by 4 hours and a 2.3-fold reduction from 
baseline by Day 3 post-treatment. This occurrence shifted the ratio of intratumoral Treg 
vs Tconv from 1:1 in untreated tumors, to 1:3 by 4 hours, and 2:7 by Day 3 post-treatment 
(Fig. 7G). 
 While the observed intratumoral Treg reduction is favorable for cancer treatment 





study the treatment impact on their phenotypic dynamics. To address this challenge, I 
used dLN, spleen, and blood tissues to better explore these dynamics. I found that the 
percentage of Tregs among CD4 cells significantly decreased (Fig. 7B and D) and the 
CD4 Tconv:Treg ratio increased in the dLN (Fig. 7E) following NPT. These changes were 
seen rapidly (by 4 hours) in the local tumor and dLN (Fig. 7D and F) and in the blood (by 
Day 1) (Fig. 7B). On the other hand, the spleen, which is used to assess long-term 
changes in immunity, demonstrated a significant reduction in Tregs by Day 3 post-
treatment and maintained its status at Day 7 post-treatment (Fig. 7C). 
 
Figure 7. 
Treg frequency is reduced in local and systemic tissues following NPT. A, Summary flow plots represent 
Foxp3+ Tregs and Foxp3- Tconv among the total CD4+ T cell population in the blood. The control group 











Figure 7. (Continued.) A, The treated mice were euthanized at 4 hours, 8 hours (for local tissues only), 
and on Day 1, Day 3, and Day 7 post-NPT. Their tumor tissues, tumor-draining lymph nodes (dLN), blood 
and spleens were harvested. Control tissues were obtained from mice with untreated tumors. B-F, 
Quantitative bar graphs depict the percentage of Tregs among the CD4+ T cell population (B-D) and the 
Tconv/Treg ratios (E) in the blood (B), spleen (C) and dLN (D and E). TIL Tregs are represented in 
quantitative bar graphs as the percentage of Tregs among CD4+ TILs (F) and as a standardized CD4 Treg 









Figure 8.  
NPT reduces intratumoral T cells. A and B, Summary flow plots demonstrate the impact of NPT on the total 
CD4+ TIL population (A) and on Tregs vs Tconv (B) in untreated mice and at 4 hours (shown only in B), 
Day 1 (shown only in A), Day 3 and Day 7 post-NPT. 
 
3.1.2 Decline in Treg activation after NPT 
 When evaluating for changes in the activated (CD44+CD62L-) vs naïve (CD44-
CD62L+) Treg distribution (Fig. 9A), I found that activated Tregs were the initially 
dominant Treg population -in the dLN of tumor-bearing mice- and outnumbered naïve 
Tregs at a 2:1 ratio. Following NPT, this activated:naïve Treg ratio shifted to 1:1 by Day 
1, and naïve Tregs became the dominant Treg population by post-treatment Day 3, at an 













Figure 9.  
Treg activation is reduced following NPT. A and B, Changes in activated and naïve Treg distribution in the 
dLN are represented in the summary flow plots (A) and quantitative bar graphs (B). C-E, Phenotypic 
changes in the 4-1BB activation marker expression among Foxp3+ Tregs are represented in the summary 
flow plots (C) and quantitative bar graphs (D and E) in the dLN (C and D) and spleen (E). N=4 per group. 











 I examined different Treg phenotypic markers, including CTLA-4, PD-1, CD39, 
Helios, 4-1BB, and TGFβ among CD4+ T cells in the dLN of tumor-bearing mice (Fig. 10 
and 11). CTLA-4, PD-1 and CD39 (not shown) were expressed in both Tconv and Tregs 
(Fig. 10) and did not demonstrate significant and consistent changes post-NPT. 4-1BB, 
Helios and TGFβ, on the other hand, were exclusively seen among the Treg population 
(Fig. 11) and were used to further determine how NPT affects Treg dynamics. 
 
 
Figure 10.  
Treg activation marker expression among total CD4+ T cells in the dLN of untreated mice. Flow plot 
summaries of Foxp3 co-expression with Treg phenotypic markers including Helios, TGFβ, 4-1BB (upper 






Figure 11.  
Changes in dLN Treg activation marker expression following NPT. dLN were analyzed from mice with 
untreated control tumors and post-NPT treatment Day 2. Flow plots represent the expression of Helios, 
CCR4, PD-1 and CTLA-4 markers among Foxp3+ Tregs. 
 
 4-1BB, a T cell activation marker with significant immunotherapeutic potential, was 
found to be expressed among Tregs in the dLN, tumors and spleens of tumor-bearing 
mice. 4-1BB expression was not found among a) Tregs in the blood, b) Tregs in any 
healthy (naïve) mouse tissues, or c) conventional CD4 or CD8 T cells of healthy or tumor-
bearing mice (Fig. 12). A significant reduction in the total number of 4-1BB+ Tregs in the 
dLN and spleen was observed in days 1-7 following NPT (Fig. 9C and E). Interestingly, 
there was an early transient peak among 4-1BB+ Tregs, around 2-fold increase from 
baseline, by 4 hours post-NPT in the dLN followed by a 7-fold drop by 24 hours post-






Figure 12.  
NPT-induced changes in 4-1BB and Foxp3 co-expression among CD4+ T cells in the dLN. Flow plots 
represent 4-1BB and Foxp3 analysis in CD4+ T cells in the dLN of untreated tumor-bearing mice (untreated 
control), tumor-naïve mice (negative control) and treated mice from the post-NPT 4 hours and Day 1 
timepoints. 
 
 4-1BB+ Tregs were further found to be exclusively expressed among activated 
Tregs and mostly absent among naïve Tregs in dLN of tumor-bearing mice (Fig. 13A). A 
higher TGFβ expression was also found among 4-1BB+ and activated Tregs (Fig. 13B) 
when compared to their 4-1BB- and naïve Treg counterparts. Similar to the changes in 
Treg 4-1BB+ expression, this elevated TGFβ expression among dLN Tregs had a 
transient increase from 33.2% among untreated mice to 39.2% at 4 hours post-NPT, 





Day 3 post-NPT (Fig. 14A and B). High-level TGFβ expression among activated Tregs 
also dropped post-treatment (Fig. 14C). While we could clearly observe the above 
phenotypic changes among dLN Tregs, the few remaining intratumoral Tregs post-NPT 
made it challenging to properly describe such phenotypic changes among TILs (Fig. 15). 
 
 
Figure 13.  
Comparing phenotypic characteristics among different Treg subsets in the untreated tumor dLN. A, Flow 
plots represent CD44/CD62L expression among the total Treg population (red) and 4-1BB+ subgate (blue). 







Figure 14.  
NPT reduces TGFβ expression among Tregs in the dLN. A, Flow plots represent changes in TGFβ and 
Foxp3 expression among CD4+ T cells. B, Quantitative graph of changes in TGFβ-hi expression among 
Tregs. C, Flow plots of TGFβ expression among activated vs naïve Tregs on Day 1 and Day 2 post-NPT. 








Figure 15.  
NPT severely reduces intratumoral Tregs making their activation marker expression unquantifiable post-
treatment. A and B, Flow plots representing Foxp3 co-expression with 4-1BB (A) and TGFβ (B) among 
CD4+ TILS in untreated tumors and on Day 3 and Day 7 post-NPT. 
 
3.1.3 Selective eradication of Tregs by NPT with a conservation of CD8 and CD4 
Tconv 
 To understand why NPT resulted in a remarkable decrease in Tregs but less so 
among Tconv (Fig. 7G), I next determined whether cell death occurred differentially in 
various subsets of T cells (Fig. 16). As we can see from Figure 16A-C, Tregs, including 







cell populations to exhibit statistically significant increases in apoptotic changes. Activated 
Tregs exhibited the highest level of apoptosis, seen at 4 hours post-treatment (Fig. 16B 
and D). Importantly, CD4 Tconv and CD8 T cells showed little or no change in apoptosis 
following NPT.   
Noticeably, all T cell groups, except for the naïve Treg subset, exhibited various levels of 
apoptotic death in the control mice (Fig. 16C). Therefore, I also evaluated the percent 
change among the T cell subsets from their baseline apoptotic status to post-NPT 
apoptosis at 4 hours post-treatment (change in T cell subset apoptosis = % apoptosis at 
4 hour post-treatment / % apoptosis in untreated control sample). Tregs exhibited the 
highest change in apoptosis at 4 hours post-NPT. Activated Tregs, in particular, 
demonstrated a 53.7% increase in apoptosis (Fig. 16D), whereas CD8 T cells showed no 









Figure 16.  
Changes in apoptosis among T cells subsets following NPT. A and B, Summary flow plots represent 
Annexin V expression among activated and naïve Treg subsets in the dLN at 4 hours and Day 1 post-NPT. 
C, Quantitative graph shows Annexin V expression among CD8, CD4 Tconv, CD4 total Treg, activated 








Figure 16. (Continued.) D, Quantitative graph shows the percent increase in Annexin V expression from 
the untreated Control to Day 1 post-treatment among T cell subsets. N=4 per group. Error bars, SD. ** p < 
0.01 and * p < 0.05 determined by one-way ANOVA. 
 
 To gain a better understanding of how NPT impacts tumor cells and their 
subsequent interaction with T cells, I pulsed cultured 4T1-luc tumor cells in vitro then co-
cultured them with healthy dLN lymphocytes. I found that healthy Tregs underwent 
apoptosis within 24 hours when co-cultured with NPT-treated tumor cells (Fig. 17A). On 
the other hand, healthy lymphocytes cultured with unpulsed (control) tumor cells were still 
alive in the co-culture after 48-72 hours, suggesting that Tregs heavily rely on healthy 
tumor presence for their survival (Fig. 17A). Tregs demonstrated increased apoptosis 






 Figure 17.  
T cells co-cultured with NPT-treated 4T1-luc cells demonstrate an increased expression in apoptosis 
markers. A, Changes in Treg apoptosis markers after 1 day and 48-72 hours in a culture with NPT-treated 
4T1-luc cells. B, Expression of apoptosis markers among different T cell subsets (Treg and CD4/CD8 
Tconv) after 1 day in a culture with NPT-treated 4T1-luc cells. C, Changes in Treg percentage among CD4+ 
T cells after 1 day in a culture with NPT-treated 4T1-luc cells. Sham experiment represents T cells cultured 






3.1.4 NPT is unlikely to influence Treg reprogramming 
 I investigated for NPT-induced Treg reprogramming to a Th17 (IL-17, RORγt 
expression) or Th1 (IFNγ expression) profile but were unable to find any significant 
changes. No FOXP3-RORγt co-expression was found in untreated or days 1, 3, 7 post-
treatment groups in local or systemic organs. 
3.1.5 No conclusive findings on the NPT impact on chemotaxis  
 Our studies on the NPT-associated changes among Treg vs Tconv CCR4 
expression are currently inconclusive and require further in vitro investigations using 
transwell assays. 
3.1.6 Differential changes in MDSCs and TAMs following NPT 
 In addition to Tregs, there are other immunosuppressive cells influencing the TME, 
including MDSCs and TAMs. TAMs (Fig. 18A and B) along with the systemic (Fig. 18C 
and D) and local (Fig. 18E and F) MDSC populations were significantly reduced following 
NPT. While investigating the intratumoral immune cell changes, I performed backgating 
to study the distribution of intratumoral TAMs, MDSCs and CD3 lymphocytes on the 
forward and side scatter plot and found that NPT affected these cell populations differently 
(Fig. 19A-D). TAMs showed a rapid decrease in cell count (by 4 hours post-treatment) 
(Fig. 19A and B), associated with a significant increase in apoptosis (Fig. 19D and E) 
and remained below control levels on days 1 and 3 post treatment (Fig. 19B). In contrast, 
MDSCs remained at control levels 1 day after treatment, but decreased by Day 3 (Fig. 
19A and B). While CD3 TILs had a similar decrease in cell count 4 hours after treatment 
(Fig. 19A and B), they exhibited no significant change in apoptosis in the tumor. By 4 





tumor. By Day 3, as MDSCs regressed, there was a significant increase in antitumor 
CD86+ M1 TAMs (Fig. 19C). 
 
 
Figure 18.  
MDSCs and TAMs are decreased following NPT. F4/80+CD11b+ TAMs in the dLN (A and B) and Gr-1+ 
CD11b+ MDSCs in the blood (C and D) and dLN (E and F) are represented as a percentage among total 
single events in the summary flow plots (A, C and E) and quantitative bar graphs (B, D and F). A 
standardized cell count is represented for TAMs in the dLN (B) and MDSCs in the blood (D) and dLN (F). 








Figure 19.  
The impact of NPT on intratumoral TAM and MDSC characteristics. A and B, Changes in intratumoral 
TAMs, MDSCs and CD3 lymphocytes distribution at 4 hours, Day 1 and Day 3 post-treatment shown in a 
summary flow plot (A) and quantitative graph (B). C, Changes in the CD86 activation marker expression 
among TAMs is investigated on the third day post-treatment, represented in a summary flow plot. D and E, 
Intratumoral TAM apoptosis summary flow plot (D) and quantitative graph (E) are shown at 4 hours and 8 












3.1.7 CD8 resident memory cells increase following NPT 
 To further evaluate the antitumor immune response, I investigated for the presence 
of resident memory T cells (Trm) following NPT.  I found an increase in the expression of 
the CD103 Trm marker among CD8 T cells in the dLN (Fig. 20A-C). The frequency of 
Trms among the CD8+ T cell population (Fig. 20A and B) and the total number of CD8 
Trms (Fig. 20C) significantly increased to 2.5-fold in the dLN following NPT. To assess 
whether this shift held potential clinical relevance, I evaluated the CD8 Trm / CD4 Treg 




Figure 20.  
CD8 Trm increase in the dLN following NPT.  
A 





Figure 20. (Continued.) A and B, Summary flow plot (A) and quantitative bar graph (B) represent CD103 
expression among the total CD8 T cell population in the dLN on days 3 and 7 following NPT. C and D, The 
Trm standardized cell count (C) and CD8 Trm / CD4 Treg ratio (D) are represented in quantitative graphs. 
N=4 per group. Error bars, SD. ** p < 0.01 and * p < 0.05 determined by one-way ANOVA. 
 
3.2 Reduction in Treg suppression capacity following treatment 
 To show the effect of NPT on the Treg suppression capacity, I isolated dLN 
CD4+CD25+ Tregs using magnetic beads and incubated them with CFSE-labelled CD8 
cells at different Treg:CD8 ratios in the presence of activation beads. Tregs isolated from 
dLNs of NPT-treated mice exhibited a reduced suppression capacity compared to those 
from untreated tumors, particularly at the Treg:CD8 1:1 and 1:2 ratios (Fig. 21). Tregs 
from both control and treatment groups were stained with Foxp3 following bead-based 







Figure 21.  
Treg suppressive function is reduced following NPT.  A, Tregs from dLN of NPT-treated mice have a 
reduced functional suppression capacity as shown in the in vitro suppression assay quantitative plot. dLN 
Tregs were incubated with CFSE-labelled CD8 responder cells at the Treg:Tresponder ratios 1:1, 1:2 and 
1:4 for 60 hours in the presence of CD3/CD28 activation beads. %Suppression = [1-(%proliferating Tresp 
at Treg:Tresp ratio / %proliferating Tresp-only cells)] x100. B, Representative histogram plots of responder 
cell proliferation alone (proliferating cells shown in the blue histogram; non-proliferating cells shown in the 
red histogram). C and D, Representative histogram plots of responder cell proliferation in the presence of 
Tregs from untreated tumor-bearing mice (control group) (C) or Tregs from NPT-treated mice (treatment 


























Figure 22.  
Purity analysis of Tregs isolated from dLNs. A and B, Summary flow plots demonstrate Foxp3 expression 
among CD4+CD25+ T cells isolated from untreated tumor-bearing mice (control group) (A) or NPT-treated 
mice (treatment group) (B). The percentage of CD4+Foxp3+ Tregs is represented among the total isolated 
CD4+CD25+ cell population. 
 
3.3 Treg TCR studies, human 
 Since functionally superior Tregs were downregulated, and activated Tregs 
underwent apoptosis following NPT, I hypothesize that the above NPT-impacted 
population consisted of clonally expanded antigen-specific Tregs. The increased 
vulnerability of activated Tregs to apoptosis in comparison to Tconv and naïve Tregs is 
discussed further in Section 4.2. The future goal of this project is to determine whether 









immunity, similar to the way it does in mice. To initiate such studies on human tissue, I 
first investigated the Treg TCR clonality in normal donor blood samples.  
3.3.1 Pure Tregs were isolated through automated cell sorting  
 To investigate the Treg TCR clonality among healthy donors, 7 blood samples from 
7 different donors were obtained from BioChemed Services. Donors were from both 
sexes; all were non-smokers and reported to be healthy. PBMCs were isolated from 
freshly drawn blood, and CD4+ cells were enriched using microbeads. The cells were then 
labeled with fluorochrome-conjugated antibodies and automated cell sorting was 
performed using the gating strategy discussed in Section 2.2.4 for the isolation of human 






Figure 23.  
Gating strategy for isolation of human CD4+CD25+CD127lo Tregs from enriched peripheral blood CD4+ T 
cells using automated cell sorting. A, Microbead-enriched CD4+ T cells from the peripheral blood of normal 
donor were initially assessed for their CD25+ expression, represented on a histogram. B, The forward 
scatter (FSC) vs side scatter (SSC) flow plot was used to select lymphocytes. C and D, Lymphocytes were 
then gated on the FSC-A vs FSC-P axis to eliminate doublets (C) and CD4+ singlets were selected (D). E, 









 The percentage of Tregs among the CD4 population was analyzed prior to sorting.  
Among the 7 normal donor blood samples, Tregs represented 7.06% of the CD4 cell 
population. The range was 4.37 - 9.10% (Table 1).   
 Following cell sorting, the isolated pure Treg population and the non-Treg CD4+ 
cells were analyzed.  The post-sort (Fig. 24) CD4+CD25+CD127lo Treg purity ranged from 




Figure 24.  
Post-sort analysis of isolated human peripheral blood Tregs. Flow plots represent CD4+CD25+CD127lo 







Table 1. Percentage of pre- and post-sort Tregs among the total CD4+ T cell population in healthy donor 
blood.  
 Tregs 
Normal Donor Pre-sort Post-sort 
1st 4.37 N/A 
2nd 8.04 92.07 
3rd 9.10 91.90 
4th 6.67 87.24 
5th 7.80 92.56 
6th 6.19 95.15 
7th 7.23 89.78 
Range 4.37 - 9.10 87 - 95 
Mean 7.06 91.45 
The percentage of CD4+CD25+CD127lo Tregs among CD4+ T cells from the peripheral blood of different 
healthy donors was recorded before (n=7) and after (n=6) automated cell sorting. The mean and range 
were calculated. 
 
3.3.2 FOXP3 gene is expressed among isolated Tregs 
 Semi-quantitative PCR analysis of actin, CD4 and FOXP3 expression for both the 
Treg and non-Treg CD4+ T cell fractions revealed actin and CD4 expression among both 






Figure 25.  
FOXP3 is expressed among isolated human peripheral blood Tregs and absent among non-Treg CD4+ T 
cells. Isolated human peripheral blood CD4+CD25+CD127lo Tregs (R) and the negative fraction consisting 
of CD4+CD25- T cells (C) demonstrated Actin and CD4 expression. Only the isolated Tregs had FOXP3 
expression. 
 
 The Treg cDNA was used as a template for alpha-chain TCR amplification with the 
32 alpha-chain family primers. The same process was repeated for beta-chain TCR 
amplification using the 24 beta-chain family primers. Two rounds of PCR amplifications 
(in a nested design) were carried out for each chain, followed by cloning and sequencing. 





3.3.3 Treg TCR analysis among healthy donors revealed mostly a polyclonal 
distribution  
 The Treg cDNA was used as a template for alpha-chain TCR amplification with the 
32 alpha-chain family primers. The same process was repeated for beta-chain TCR 
amplification using the 24 beta-chain family primers. Two rounds of PCR amplifications 
(in a nested design) were carried out for each chain, followed by cloning and sequencing. 
The obtained TCR sequences were then analyzed using the IMGTV & Expasy softwares. 
ND1Treg  
Sequence analysis of the beta-chain TCR transcripts of the 1st normal donor Treg sample 
(ND1Treg) revealed two quadruplets, a triplet, and five doublets (Table 2): 
(1) clone ND1Treg-B-1:  transcript Vβ11.2 Dβ1 Jβ1.2; CDR3 sequence 
CASSLEGGPQRGYTF accounted for 4 of 36 (11.11%) of the beta-chain TCR transcripts 
sequenced. 
(2) clone ND1Treg-B-2:  transcript Vβ5.1 Dβ1 Jβ1.4; CDR3 sequence 
CASSVDRGKEKLFF accounted for 4 of 36 (11.11%) of the beta-chain TCR transcripts 
sequenced. 
(3) clone ND1Treg-B-3:  transcript Vβ18 Dβ1 Jβ2.5; CDR3 sequence CASSPDSQETQYF 
accounted for 3 of 36 (8.33%) of the beta-chain TCR transcripts sequenced. 
The following clones were doublets, and they accounted for 2 of 36 (5.56%) of the beta-
chain TCR transcripts sequenced:  





(5) clone ND1Treg-B-5: transcript Vβ5.1 Dβ2 Jβ1.1; sequence CATRDGIGINTEAFF  
(6) clone ND1Treg-B-6: transcript Vβ11.2 Dβ1 Jβ2.5; sequence CASSLVVGLPDF,  
(7) clone ND1Treg-B-7: transcript Vβ5.1 Dβ2 Jβ1.1; sequence CASNLMGGRNTEAFF,  
(8) clone ND1Treg-B-8: transcript Vβ2 Dβ1 Jβ2.1; sequence CASRPETGRNEQFF  
The remainder of the TCR sequences demonstrated a polyclonal distribution (singlets). 
 
Table 2. β-Chain TCR transcripts expressed in Tregs from 1st donor PBMCs. 
Vβ N-Dβ-N Jβ Gene usage 
tgtgccagcagctt 
 C  A  S  S  L   
ggaagggggcccacagcg 
  E  G  G  P  Q  R   
tggctacaccttc 
  G  Y  T  F  
Vβ11.2 Dβ1 Jβ1.2 
(4/36, 11.11%) 
tgcgccagcagc 
 C  A  S  S   
gtggacagggggaaa 
 V  D  R  G  K   
gaaaaactgtttttt 
 E  K  L  F  F 
Vβ5.1 Dβ1 Jβ1.4 
(4/36, 11.11%) 
tgtgccagctcacc 
 C  A  S  S  P 
tgacagt 
  D  S   
caagagacccagtacttc 
 Q  E  T  Q  Y  F 
Vβ18 Dβ1 Jβ2.5 
(3/36, 8.33%) 
tgtgccagcagttactc 
 C  A  S  S  Y  S   
tcgctcgatga 
  R  S  M  
tgaacactgaagctttcttt 




 C  A  S  S  L  
tcgtaggcctcccag 
V  V  G  L  P   
acttc 
D  F 
Vβ11.2 Dβ1 Jβ2.5 
(2/36, 5.56%) 
tgcgcca 
 C  A   
cgcgggacgggatcgggatc  
T  R  D  G  I  G  I   
aacactgaagctttcttt 
 N  T  E  A  F  F 
Vβ5.1 Dβ2 Jβ1.1 
(2/36, 5.56%) 
Tgcgccagca 
 C  A  S   
acttgatgggggggag 
N  L  M  G  G  R   
gaacactgaagctttcttt 
  N  T  E  A  F  F 
Vβ5.1 Dβ2 Jβ1.1 
(2/36, 5.56%) 
Tgtgccagcag 
 C  A  S  R 
accggagacaggccg 
  P  E  T  G  R   
caatgagcagttcttc 
  N  E  Q  F  F 
Vβ2 Dβ1 Jβ2.1 
(2/36, 5.56%) 
Tgcagcg 
 C  S   
tcccctcactagggttg 
V  P  S  L  G  L   
aatgagcagttcttc 
 N  E  Q  F  F 







Table 2. (Continued.) 
Tgtgcctggagtgt 
 C  A  W  S  V   
atcgtcagggatgtt 
 S  S  G  M  F  
tcagccccagcattt 
 Q  H  F  Q  P 
Vβ30 Dβ1 Jβ1.5 
(1/36, 2.78%) 
Tgcgccagcag 
 C  A  S  S  
tgctttaaataggggcagt 
  A  L  N  R  G  S   
tcctacaatgagcagttcttc 
 S  Y  N  E  Q  F  F 
Vβ4.1 Dβ1 Jβ2.1 
(1/36, 2.78%) 
Tgcagtgct 
 C  S  A   
gcccgggacggggggag 
 A  R  D  G  G  S  
cactgaagctttcttt 
  T  E  A  F  F 
Vβ20.1 Dβ2 Jβ1.1 
(1/36, 2.78%) 
tgcagtgctag 
 C  S  A  S   
tgtcccaggaggtgg 
  V  P  G  G  G   
cactgaagctttcttt 
  T  E  A  F  F 
Vβ20.1 Dβ2 Jβ1.1 
(1/36, 2.78%) 
tgtgccagctcacc  
 C  A  S  S  P   
ggtccgg 
  V  R  
gaagctttcttt 
 E  A  F  F 
Vβ18 Dβ2 Jβ1.1 
(1/36, 2.78%) 
tgcagtgc 
 C  S  A 
caccgggacccccg 
  T  G  T  P 
atcagccccagcatttt 
D  Q  P  Q  H  F  
Vβ20.1 Dβ1 Jβ1.5 
(1/36, 2.78%) 
Tgcagcg 
 C  S   
ttgaaaggg 
V  E  R   
accaagagacccagtacttc  
D  Q  E  T  Q  Y  F 
Vβ29 Dβ1 Jβ2.5 
(1/36, 2.78%) 
tgtgccagcagtttat 
 C  A  S  S  L   
tgtccctgactcta 
L  S  L  T  L   
gagcagttcttc  
 E  Q  F  F 
Vβ27 Dβ2 Jβ2.1 
(1/36, 2.78%) 
tgcgccagcagcttgg 
 C  A  S  S  L 
accagccatctcga 
D  Q  P  S  R   
ggctacaccttc  
 G  Y  T  F 
Vβ5.1 Dβ1 Jβ1.2 
(1/36, 2.78%) 
tgcagtgctagaga  
 C  S  A  R  D   
tttgaa 
  L  K   
gaacactgaagctttcttt  




 C  A  S  S  L 
tcgtaggcctcccag 
V  V  G  L  P   
acttc  
D  F 
Vβ11.3 Dβ1 Jβ2.5 
(1/36, 2.78%) 
tgcagtgctag 
 C  S  A  S  
tgtcccaggaggtggcacc 
 V  P  G  G  G  T   
gaagctttcttt  
 E  A  F  F 
Vβ20.1 Dβ2 Jβ1.1 
(1/36, 2.78%) 
tgcagtgctaga   
 C  S  A  R   
atggctagcgggggggctattcgtag 
 M  A  S  G  G  A  I  R  S   
cgagcagtacttc 
  E  Q  Y  F 
Vβ20.1 Dβ2 Jβ2.7 
(1/36, 2.78%) 
tgcgccagcagcttg 
 C  A  S  S  L   
accagccatttcga. 
 T  S  H  F  -   
ggctacaccttc  
 G  Y  T  F 









For the sake of clarity, the above results will be referred to as ‘all-family’ amplifications. 
To further investigate the clonal sequences observed in the Vβ11 and Vβ5 families, 
‘family-specific’ amplifications were carried out:  
Frozen ND1Treg RNA was reverse transcribed, and the cDNA template was used for two 
rounds of PCR amplifications using the Vβ11 primer for one set of PCR reactions, and 
the Vβ5 primer for another set. Cloning and sequencing were performed.  
Sequence analysis for the Vβ11 family-specific amplifications revealed (Table 3):  
clone ND1Treg-BFS11-1: transcript Vβ11.2 Dβ2 Jβ2.1; CDR3 sequence 
CASSLVGGDWHEQFF accounted for 4 of 12 (33.3%) of the beta-chain TCR transcripts 
sequenced. All other sequences were singlets. 
 
Table 3. ND1Treg Vβ11 family-specific TCR expression. 
Vβ N-Dβ-N Jβ Gene usage 
Tgtgccagcagcttag 
 C  A  S  S  L   
Tcgggggggattggc 
V  G  G  D  W   
atgagcagttcttc 
H  E  Q  F  F 
Vβ11.2 Dβ2 Jβ2.1 
(4/12; 33.3%) 
Tgtgccagcagc 
 C  A  S  S   
Ataggacaggggttg 
 I  G  Q  G  L   
aacattcagtacttc 
 N  I  Q  Y  F 
Vβ11.3 Dβ1 Jβ2.4  
(1/12; 8.3%) 
tgtgccagcagc  
 C  A  S  S   
Ataggacaggggttg 
 I  G  Q  G  L   
aacattcagtacttc  
 N  I  Q  Y  F 





 A  S  S  L  V  G  G  D  W  H   
atgagcagttcttc  
   E  Q  F  F 
Vβ11.3 Dβ2 Jβ2.1 
(1/12; 8.3%) 
Tgtgccagcagc 
 C  A  S  S   
gccttcctagcggggggct 
 A  F  L  A  G  G   
acaccggggagctgtttttt  
Y  T  G  E  L  F  F 
Vβ11.1 Dβ2 Jβ2.2 
(1/12; 8.3%) 
tgtgccagcagc  
 C  A  S  S   
ataggacaggggttgac 
 I  G  Q  G  L  T   
cattcagtacttc  
  I  Q  Y  F 







Table 3. (Continued.) 
tgtgccagcagcttag 
 C  A  S  S  L   
tcgggggggattggcatgagcagtc 
V  G  G  D  W  H  E  Q  S   
cttc 
  F 
Vβ11.2 Dβ2 Jβ2.1 
(1/12; 8.3%) 
tgtgccagcagc 
 C  A  S  S 
gccttctttcccggggggct. 
 A  F  F  P  G  G  #   
.acaccggggagctgtttttt 
 #  T  G  E  L  F  F 





L  C  Q  Q  R  L  P  S  G  G  A   
.acaccggggagctgtttttt 
 #  T  G  E  L  F  F 




Family-specific nested PCR amplifications for the Vβ5 chain revealed (Table 4):   
clone ND1Treg-BFS5-1: transcript Vβ5.1 Dβ1 Jβ1.6; CDR3 sequence 
CASRPGQFNPTFNSPLHF accounted for 4 of 6 (66.7%) of the beta-chain TCR 
transcripts sequenced. 
 
Table 4. ND1Treg Vβ5 family-specific TCR expression. 
Vβ N-Dβ-N Jβ Gene usage 
tgcgccagc  
 C  A  S   
cgtccgggacagttcaatcccagctt 
 R  P  G  Q  F  N  P  S  F 
taattcacccctccacttt 
  N  S  P  L  H  F 





  A  S  S  L  G  L  G  T   
gaacactgaagctttcttt  
  N  T  E  A  F  F 





  A  S  S  A  G  D  R  S   
actgaagctttcttt  
 T  E  A  F  F 
Vβ5.4 Dβ1 Jβ1.1 
(1/6) 
 
The expanded Vβ11 (CASSLEGGPQRGYTF) and Vβ5 (CASSVDRGKEKLFF) 
sequences obtained from the initial all-family amplifications (Table 4) did not match the 






All-family amplification of the ND1Treg alpha-chain TCR transcripts, followed by cloning 
and sequencing, revealed a triplet and a doublet: 
(1) clone ND1Treg-A-1: Vα4 Jα16 transcript; CDR3 sequence CLVGVSDGQKLLF 
accounted for 3 of 16 (18.75%) of the alpha-chain TCR transcripts sequenced. 
(2) clone ND1Treg-A-2: Vα12.2 Jα58 transcript; CDR3 sequence CAVNGPETSGSRLTF 
accounted for 2 of 16 (12.5%) of the alpha-chain TCR transcripts sequenced. 
 
Table 5. α-Chain TCR transcripts expressed in Tregs from 1st donor PBMCs. 
Vα N Jα Gene usage 
Tgcctcgtgggtg 
 C  L  V  G   
 tttcagatggccagaagctgctcttt 




 C  A  V  N   
Gggcc 
 G  P   
agaaaccagtggctctaggttgaccttt  




 C  L  V  G   
ta 
V   
tcagatggccagaagctgctcttt 




 C  A  A  S   
gggtctcagggg 
 G  S  Q  G   
ggaaatgagaaattaaccttt 






 P  A  E  T  S  G  S   
ggttgaccttt 




 C   
ccagcc   
 P  A   
gaaaccagtggctctaggttgaccttt 












 C  A  A   
gcagg 
 A  G   
tacctcaggaacctacaaatacatcttt  




 C  A  A   
gcaggtacctcg 
 A  G  T  S   
ggaacctacaaatacatcttt 








Table 5. (Continued.) 
C ctgcaaggttacaactggtggagcaacctatggcc 
P  A  R  L  Q  L  V  E  Q  P  M  A   
.agctgacattt 




   
agctgtgccc 
  A  V  P   
cagggcggatctgaaaagctggtcttt 
Q  G  G  S  E  K  L  V  F 
Vα21 Jα57 
(1/16, 6.25%) 
- - - Vα4 Jα43 
(1/16, 6.25%) 
 
Vα4 family-specific amplifications, cloning and sequencing revealed (Table 6): 
clone ND1Treg-A4FS-1: Vα4 Jα20 transcript; CDR3 sequence CLVGDRDYKLSF 
accounted for 18 of 23 (78.3%) of the alpha-chain TCR transcripts sequenced. 
A clonal expansion was observed of the Vα4 Jα20 TCR transcript sequence 
CLVGDRDYKLSF with 18/23 identical copies of the sequence present. This constituted 
78.3% of the sequences; the remainder of the sequences were singlets. 
 
Table 6. ND1Treg Vα4 family-specific TCR expression 
Vα N Jα Gene usage 
tgcctcgtgggtgaca 
 C  L  V  G  D   
ga  
R   
gactacaagctcagcttt  





Analysis of the ND2Treg beta chain TCR transcripts revealed a polyclonal distribution of 






Table 7. β-Chain TCR transcripts expressed in Tregs from 2nd donor PBMCs 
Vβ N-Dβ-N Jβ Gene usage 
tgtgccagcag 
 C  A  S  S  
cctgtacccgacagggaa 
  L  Y  P  T  G  N   
ctacgagcagtacttc 
  Y  E  Q  Y  F 
Vβ27 Dβ1 Jβ2.7 
(1/19, 5.26%) 
tgtgccagcagccaag 
 C  A  S  S  Q   
gggatcc 
G  D  P   
caatgagcagttcttc  
  N  E  Q  F  F   
Vβ14 Dβ1 Jβ2.1 
(1/19, 5.26%) 
tgtgccagctcacc  
 C  A  S  S  P   
gggactagcgggag 
  G  L  A  G   
cagatacgcagtatttt  
A  D  T  Q  Y  F 
Vβ18 Dβ2 Jβ2.3 
(1/19, 5.26%) 
tgtgcctgg 
 C  A  W   
agtatgagcagac  
 S  M  S  R   
acgagcagtacttc 
H  E  Q  Y  F 
Vβ30 Dβ1 Jβ2.7 
(1/19, 5.26%) 
tgcgccagcag 
 C  A  S  R   
gacggacaagcc  
  T  D  K  P   
caccggggagctgtttttt 
  T  G  E  L  F  F 
Vβ5.1 Dβ1 Jβ2.2 
(1/19, 5.26%) 
tgcagtgctagag 
 C  S  A  R   
tgcggag 
V  R  S 
ctcctacaatgagcagttcttc  
  S  Y  N  E  Q  F  F 
Vβ20.1 Dβ2 Jβ2.1 
(1/19, 5.26%) 
tgcagtgctag 
 C  S  A  S   
tggcag 
  G  S   
ctacgagcagtacttc  
  Y  E  Q  Y  F 
Vβ20.1 Dβ1 Jβ2.7 
(1/19, 5.26%) 
tgcagtgctagag  
 C  S  A  R   
gtcacgggggc 
G  H  G  G   
aacactgaagctttcttt  
 N  T  E  A  F  F 
Vβ20.1 Dβ1 Jβ1.1 
(1/19, 5.26%) 
tgtgcctgg 
 C  A  W   
gcccacaccttcg  
 A  H  T  F   
acactgaagctttcttt 
D  T  E  A  F  F 
Vβ30 Dβ1 Jβ1.1 
(1/19, 5.26%) 
tgtgccagca 
 C  A  S   
ccaccgccggacggag  
T  T  A  G  R  S   
ctcctacaatgagcagttcttc 
  S  Y  N  E  Q  F  F 
Vβ28 Dβ1 Jβ2.1 
(1/19, 5.26%) 
tgcgccagcagct 
 C  A  S  S   
gggggggacta 
W  G  G  L 
caagagacccagtacttc 
 Q  E  T  Q  Y  F 
Vβ5.1 Dβ2 Jβ2.5 
(1/19, 5.26%) 
tgcagtgc 
 C  S  A   
ctcccgggacggg  
  S  R  D  G   
aactatggctacaccttc 
 N  Y  G  Y  T  F 
Vβ20.1 Dβ1 Jβ1.2 
(1/19, 5.26%) 
tgcagtgc 
 C  S  A   
cagcgccactacagggggctacgagcagtacc  
  S  A  T  T  G  G  Y  E  Q  Y   
tc 
L 
Vβ20.1 Dβ1 Jβ2.7 
(1/19, 5.26%) 
tgcgccagcagcttgg 
 C  A  S  S  L   
g  
G   
ctctggggccaacgtcctgactttc 




 C  A  S  S   
ctccgggacagggggcgg 
 S  P  G  Q  G  A   
actatggctacaccttc  
D  Y  G  Y  T  F 







Table 7. (Continued.) 
tgtgccagcagtt 
 C  A  S  S   
ctcgacagggcgag  
S  R  Q  G  E 
tatggctacaccttc 
 Y  G  Y  T  F 
Vβ27 Dβ1 Jβ1.2 
(1/19, 5.26%) 
tgtgccagca  
 C  A  S   
ccaggacagggggtactgg 
T  R  T  G  G  T  G   
tggctacaccttc  
  G  Y  T  F 
Vβ28 Dβ1 Jβ1.2 
(1/19, 5.26%) 
tgtgccagcagccaag 
 C  A  S  S  Q   
gggagagg 
G  E  R   
gatacgcagtatttt  
 D  T  Q  Y  F 
Vβ14 Dβ2 Jβ2.3 
(1/19, 5.26%) 
tgtgccagcagcg  
 C  A  S  S   
cccacgggacagggggg 
A  H  G  T  G  G   
tcacccctccacttt  
 S  P  L  H  F   




Analysis of the ND2Treg alpha chain TCR transcripts (Table 8), on the other hand, 
revealed a triplet and a doublet: 
(1) clone ND2Treg-A-1:  transcript Vα22 Jα57; CDR3 sequence CAVKSQGGSEKLVF 
accounted for 3 of 24 (12.5%) of the alpha-chain TCR transcripts sequenced 
(2) clone ND2Treg-A-1: transcript Vα39 Jα40; CDR3 sequence CAVEIPGTYKYIF 
accounted for 2 of 24 (12.5%) of the alpha-chain TCR transcripts sequenced following 
two sets of nested all-family amplifications. 
 
Table 8. α-Chain TCR transcripts expressed in Tregs from 2nd donor PBMCs 
Vα N Jα Gene usage 
tgtgctgtg  
 C  A  V   
aagt 
 K   
ctcagggcggatctgaaaagctggtcttt 




 C  A  V  E   
gatcc 
  I     
caggaacctacaaatacatcttt  




 C  A  L   
ccc 
  P   
ctctggggctgggagttaccaactcactttc 







Table 8. (Continued.) 
tgtgcagagaata  
 C  A  E  N   
aggccccggacgactacaagctcaa 
K  A  P  D  D  Y  K  L  N   
cttt 




 C  A  V  E  R   
g  gggtacagcagtgcttccaagataatcttt 




 C  A  G  Q   
caac 
 Q   
gttctaacgactacaagctcagcttt  




 C  G  
gagg 
G  G   
ctcaggaacctacaaatacatcttt  




 C  A   
gg 
G    
acaggctttcagaaacttgtattt  




 C  A  L  D   
 taaccagggaggaaagcttatcttc 




 C  A  V  E 
gcggtagcg 
R  G  S   
actatcagttaatctgg  




 C  G  A  D   
ccggaaagaacctgcaaaaac 
 P  E  R  T  C  K  N   
atcttt 




 C  A  L  D   
 taaccagggaggaaagcttatcttc 






 V  V  T  L  V   
ggaacctacaaatacatcttt 




 C  A  L   
caa 
  K   
gatttataaccagggaggaaagcttatcttc 




 C  A   
cggcgtgaattatggaggaagccag 
 G  V  N  Y  G  G  S  Q   
ggaaatctcatcttt 




L  C  C  G  G  S  G  G  S  Y  I  P 
actttt 




 C  A  V  S   
tgataagggcggatatgaaaagct. 
  D  K  G  G  Y  E  K  L   
gtcttt  




 C  A   
gcccaaaaagaggagggg..caaggaaatct 
G  P  K  R  G  G  -  Q  G  N  L     
catcttt 




 C  A   
tgctaacttgggaaaaaaga.. 
  A  N  L  G  K  K  - 
aaattaaccttt 







Table 8. (Continued.) 
tgt   
 C 
tttttcccggaggggaaggaa.  
 F  F  P  E  G  K  E   
gaaatgagaaattaaccttt 




 C  A  L   
ccggtaaccattttcttt. 
A  G  N  H  F  L  - 
Tttt 




Using the same ND2Treg RNA, Vα22 family-specific PCR amplification of the cDNA 
product (Table 9), revealed a doublet:  
Clone ND2Treg-A22FS-1: Vα22 Jα4 transcript; CDR3 sequence CAVHSGGYNKLIF 
accounted for 2 of 11 (18.8%) of the Vα22 TCR transcripts sequenced. The remainder 
were singlets.  
 
Table 9. ND2Treg Vα22 family-specific TCR expression 
Vα N Jα Gene usage 
tgtgctgt  
 C  A  V   
cca 
  H 
ttctggtggctacaataagctgattttt 




 C  A  V   
ccattcc  
  H  S   
ggtggctacaataagctgattttt 




 C  A   
 ggatggatagcagctataaattgatcttc 




 C  A   
ggatggatagcagcc 
G  M  D  S  S 
ataaattgatcttc 




 C  A  V   
ttt 
 L   
agaaaccagtggctctaggttgaccttt 




 C  A  V   
 ggtacagcagtgcttccaagataatcttt 




 C  A  V   
aggg 
 R   
atagtggaggtagcaactataaactgacattt 







Table 9. (Continued.) 
tgtgct  
 C  A   
tcccg 
 S  R   
gaacagagatgacaagatcatcttt 




 C  A  V  E   
cc 
P   
aacaccaatgcaggcaaatcaaccttt 




 C  A  V   
agc  
  A   
tactggagccaatagtaagctgacattt 





The third Treg isolation ND3Treg sample revealed unique sequences for both chains, 
indicating a polyclonal distribution among the Tregs. 17 beta chains and 13 alpha chains 
were sequenced. 
ND4Treg 
The fourth Treg isolation ND4Treg sample similarly revealed unique TCR transcript 
sequences for both chains; 21 beta chains and 18 alpha chains were sequenced. 
ND5Treg 
The fifth Treg isolation ND5Treg sample produced three doublets in the alpha chain 
(Table 10):  
(1) clone ND5Treg-A-1:  transcript Vα22 Jα42; CDR3 sequence CAVGRGGSQGNLIF 
accounted for 2 of 24 (8.33%) of the alpha-chain TCR transcripts sequenced 
(2) clone ND5Treg-A-2: transcript Vα34 Jα21; CDR3 sequence CGAATGWDKFYF 





(3) clone ND5Treg-A-3: transcript Vα6 Jα12; CDR3 sequence CALLDSSYKLIF 
accounted for 2 of 24 (8.33%) of the α-chain TCR transcripts sequenced. 
 
Table 10. α-Chain TCR transcripts expressed in Tregs from 5th donor PBMCs. 
Vα N Jα Gene usage 
tgtgctgtgg 
 C  A  V   
gtcgg 
G  R    
ggaggaagccaaggaaatctcatcttt 




 C  G  A  
cgacagggtggg 
A  T  G  W   
acaaattttacttt 




 C  A  L   
t tggatagcagctataaattgatcttc 




 C  A   
ccaggggagagatgacaagg 
  Q  G  R  D  D  K     
tcatcttt 




 C  A  M  R  D   
tcag 
  Q   
tcaggaaacacacctcttgtcttt  




 C  A  V   
ctct 
T  L 
caccgacaagctcatcttt 




 C  A  E   
ca 
 Q   
aggaagctacatacctacattt 




L  A  M  S  P  N  P  G  N  Q  F  F   
tttt  




 C  L  L   
cctctctgc 
  L  S  A   
ggataactatggtcagaattttgtcttt 




 C  A  L   
cctatc 
T  Y   
cttataacaccgacaagctcatcttt 




 C  A  V   
a caggaaacacacctcttgtcttt 




 C  A  
catggcat 
 H  G  I   
ctcaggaacctacaaatacatcttt 








Table 10. (Continued.) 
tgtgcagca 
 C  A  A   
ggag 
 G  
acaccgacaagctcatcttt 




 C  A   
ggttca 
 G  F  
tgttttctggtggctacaataagctgatt
ttt 




 C  A  V  E   
 ggatggatagcagctataaattgatctt
c 




 C  A  T  D   
cggg 
A  G 
ctatggtcagaattttgtcttt 




 C  A   
ccagggg 
 Q  G   
agagatgacaagatcatcttt 












 C  A  V   
cccgggg 
P  G   
ggtagcaactataaactgacattt 




 C  A  G  Q   
tcttatcagggagcccagaagctggtatc 
 S  Y  Q  G  A  Q  K  L  V  S 
T Vα35 Jα54 
(1/24; 4.17%) 
tgtgcagcaagt  
 C  A  A  S   
ctgaatgcaggcaaatcaacc 








The sixth Treg isolation ND6Treg sample had unique TCR transcript sequences for the 








Table 11. β-Chain TCR transcripts expressed in Tregs from 6th donor PBMCs. 
Vβ N-Dβ-N Jβ Gene usage 
tgtgccag 
 C  A  S  
tagcttacttgcgactaa 
  S  L  L  A  T  N   
ctctggaaacaccatatatttt  
  S  G  N  T  I  Y  F 
Vβ11.2 Dβ2 Jβ1.3 
(1/23: 4.35%) 
tgtgccagcagc 
 C  A  S  S  
ctgggtgacgggtctc 
 L  G  D  G  S   
acaatgagcagttcttc 
H  N  E  Q  F  F 
Vβ11.2 Dβ2 Jβ2.1 
(1/23: 4.35%) 
tgtgccagcag 
 C  A  S  S   
tactaggcggggag 
  T  R  R  G   
ctgaagctttcttt 
A  E  A  F  F 
Vβ11.2 Dβ2 Jβ1.1 
(1/23: 4.35%) 
tgtgccagcagc 
 C  A  S  S   
ccgggggcagggggcgg  
 P  G  A  G  G  G 
caccggggagctgtttttt 
  T  G  E  L  F  F 
Vβ11.2 Dβ1 Jβ2.2 
(1/23: 4.35%) 
tgtgccagcagctt 
 C  A  S  S  F 
tcaggagaactatggca 
  Q  E  N  Y  G   
acaccttc  
N  T  F 
Vβ11.2 Dβ1 Jβ1.2 
(1/23: 4.35%) 
tgtgccagcagctt 
 C  A  S  S  F  
tcaggag 
  Q  E 
aactatggctacaccttc 
 N  Y  G  Y  T  F 
Vβ11.2 Dβ1 Jβ1.2 
(1/23: 4.35%) 
tgtgccagctc 
 C  A  S  S   
ccccggccgcgccgggggccg 
  P  G  R  A  G  G  R   
caatgagcagttcttc 
  N  E  Q  F  F 
Vβ18 Dβ1 Jβ2.1 
(1/23: 4.35%) 
tgtgccagctcaccac 
 C  A  S  S  P  
tcgggacagggggcggg 
L  G  T  G  G  G 
aatgagcagttcttc 
 N  E  Q  F  F 
Vβ18 Dβ1 Jβ2.1 
(1/23: 4.35%) 
tgtgccagctcac 
 C  A  S  S   
aacaaggagggga  
Q  Q  G  G  D   
taatgaaaaactgtttttt 
  N  E  K  L  F  F 
Vβ18 Dβ2 Jβ1.4 
(1/23: 4.35%) 
tgtgccagcagt 
 C  A  S  S   
cacggactagcggggggtctt 
 H  G  L  A  G  G  L   
gatacgcagtatttt 
 D  T  Q  Y  F  
Vβ6.1 Dβ2 Jβ2.3 
(1/23: 4.35%) 
tgtgccagc 
 C  A  S   
gcacctacggctagcggggggggcgg  
 A  P  T  A  S  G  G  G  G   
ctcctacaatgagcagttcttc 
  S  Y  N  E  Q  F  F 
Vβ6.1 Dβ2 Jβ2.1 
(1/23: 4.35%) 
tgcagtg 
 C  S 
ggcaggggcta 
G  Q  G  L   
acagatacgcagtatttt 
 T  D  T  Q  Y  F 
Vβ20.1 Dβ1 Jβ2.3 
(1/23: 4.35%) 
Tgcag 
 C  R   
agctagaggcagggtaacggg  
  A  R  G  R  V  T  G   
cggggagctgtttttt  
  G  E  L  F  F 
Vβ20.1 Dβ1 Jβ2.2 
(1/23: 4.35%) 
tgtgccag  
 C  A  S   
cagaccgggactagcgggggtggt 
  R  P  G  L  A  G  V  V   
agatacgcagtatttt  
  D  T  Q  Y  F 
Vβ3.1 Dβ2 Jβ2.3 
(1/23: 4.35%) 
tgcgccagcag  
 C  A  S  R    
acgtcaggtct 
  R  Q  V   
caactaatgaaaaactgtttttt  
S  T  N  E  K  L  F  F 







Table 11. (Continued.) 
tgtgccagcagcc 
 C  A  S  S   
gccagggaggaaggtc  
R  Q  G  G  R  S  
cactgaagctttcttt 
  T  E  A  F  F  
Vβ14 Dβ2 Jβ1.1 
(1/23: 4.35%) 
tgtgccagcag 
 C  A  S  S   
ccatatcagggagggggg  
  H  I  R  E  G  G 
ctatggctacaccttc 
  Y  G  Y  T  F  
Vβ25.1 Dβ2 Jβ1.2 
(1/23: 4.35%) 
tgtgccatcagtga  
 C  A  I  S  E   
agttcgg 
 V  R   
gaaaaactgtttttt  
 E  K  L  F  F 
Vβ10.3 Dβ2 Jβ1.4 
(1/23: 4.35%) 
tgtgccag 
 C  A  R  
aagattgataagtag 
  R  L  I  S  S   
ctcctataattcacccctccacttt  
  S  Y  N  S  P  L  H  F 
Vβ2 Dβ2 Jβ1.6 
(1/23: 4.35%) 
tgtgcctggag 
 C  A  W  S   
tttcagcagtaaa 
  F  S  S  K   
tatggctacaccttc 
 Y  G  Y  T  F 
Vβ30 Dβ1 Jβ1.2 
(1/23: 4.35%) 
tgtgccagcagttt 
 C  A  S  S  F 
tgggc  
  G 
cgaattcacccctccacttt 
P  N  S  P  L  H  F 
Vβ27 Dβ1 Jβ1.6 
(1/23: 4.35%) 
tgcgccagcagcttgg     
 C  A  S  S  L   
cggcagat 
A  A  D   
tatggctacaccttc  
 Y  G  Y  T  F 
Vβ1 Dβ1 Jβ1.2 
(1/23: 4.35%) 
tgtgccagcagct 
 C  A  S  S   
cgaggacaggggg 
S  R  T  G  G   
ctacaatgagcagttcttc  
  Y  N  E  Q  F  F 




All-family Nested PCR amplifications revealed a quadruplet (Table 12):  
clone ND6Treg-A-1:  transcript Vα22 Jα45; CDR3 sequence CAVERFGRGGADGLTF 
accounted for 4 of 26 (15.4%) of the alpha-chain TCR transcripts sequenced following 















Table 12. α-Chain TCR transcripts expressed in Tregs from 6th donor PBMCs. 
Vα N Jα Gene usage 
tgtgctgtggagc 
 C  A  V  E  
Ggttcggaa 
R  F  G   
gaggaggtgctgacggactcaccttt 




 C  A  V  E   
atctaacgacc  
  S  N  D   
acaagctcagcttt 




 C  A  V  E   
a  tctaacgactacaagctcagcttt 




 C  A   
ctaga  
A  R   
tcttataacaccgacaagctcatcttt 




 C  G  A  D 
tacc  
I  P   
caccaatgcaggcaaatcaaccttt 




 C  A  V   
 gcggatctgaaaagctggtcttt 













 C  A  V   
 ccggtaaccagttctatttt 








 G  G  A  T  N  K  L  I  F 
Vα41 Jα32 
(1/26: 3.85%) 
tgtgcagagagta    
 C  A  E  S   
gaccgggggcaaacaacctcttct 






 C  A  E   
tccaac 
S  N   
aaccagggaggaaagcttatcttc 




 C  A  E   
cccctact  
T  P  T   
ttttctggtggctacaataagctgattttt 






G  A  P  N  D  R  G  Q  G  G  K  L   
atcttc 




 C  V  V  N  
gatttctggggtacgggcaggagagcacttacc 






 C  G  A  
ccgcagggg  
  R  R  G 
cggcactgccagtaaactcaccttt 







Table 12. (Continued.) 
tgtcttct 
 C  L  L   
c ggaggaggtgctgacggactcaccttt 




 C  A  V   
ggtg  
 G   
attctgggggttaccagaaagttaccttt 




 C  A   
ccctcgcgcagctggaggcttcaaaactatcttc  
  P  R  A  A  G  G  F  K  T  I  F 
 Vα6 Jα9 
(1/26: 3.85%) 
tgtgctgtgcagg 
 C  A  V  Q 
aatatat  
E  Y  I   
caccaatgcaggcaaatcaaccttt 




 C  A  V   
tccttac 
V  L  T   
gaacagagatgacaagatcatcttt 




 C  A  V  E   
gag 
  S   
tgcaggcaacatgctcaccttt  




 C  A  T  D   
tacgg  
 Y  G   
taatgctggtggtactagctatggaaagctgac
attt 




 C  A  A   
cccct  
T  P   
tacagcagtgcttccaagataatcttt 





Vα22 family-specific PCR amplification of the ND6Treg RNA material revealed a triplet 
and a doublet (Table 13): 
(1) clone ND6Treg-A22FS-1; TCR transcript Vα22 Jα12; CDR3 sequence 
CAGMDSSYKLIF accounted for 3 of 21 (14.3%) of the Vα22 transcripts sequenced. 
(2) clone ND6Treg-A22FS-2; TCR transcript Vα22 Jα26; CDR3 sequence 







Table 13. ND6Treg Vα22 family-specific TCR expression. 
Vα N Jα Gene usage 
tgtgctg 
 C  A   
 ggatggatagcagctataaattgatcttc 




 C  A   
ctgaac  
 L  N   
gataactatggtcagaattttgtcttt 




 C  A  V   
gt 
G   
aataacaatgccagactcatgttt 




 C  A  V   
gtaataacaatgccagactcatgtc 






 C  A  G 
 gagatgacaagatcatcttt 




 C  A   
gagatgacaagatcatcttc 
G  D  D  K  I  I  F 
 Vα22 Jα30 
(1/21: 4.76%) 
tgtgctgt 
 C  A  V  
cca  
  H   
ttctggtggctacaataagctgattttt 




 C  A  V   
agc  
  A   
tactggagccaatagtaagctgacattt 




 C  A  V  D   
tagaactggggcaaacaat 
  R  T  G  A  N  N   
ctcttcttt 




 C  A  V  E   
ttc  
L   
attcaggaaacacacctcttgtcttt 




 C  A  V   
tgtcgtgt  
 C  R  V 
tagcaactatcagttaatctgg 




 C  A  V   
g  
G   
ccaggcaggaactgctctgatcttt 




 C  A  V  E   
agagctg 
 R  A 
ccggcactgccagtaaactcaccttt 












 C  A  V   
atccca  
 I  P   
tacaacttcaacaaattttacttt 








Table 13. (Continued.) 
Tgtgctg 
 C  A   
ctaga 
A  R   
tcttataacaccgacaagctcatcttt 




 C  A   
ggggggggt 
G  G  G   
acaataacaatgacatgcgcttt 




 C  A  V  E   
gggcgc  
 G  R 
ggctctggcaacacaggcaaactaatcttt 






The seventh Treg isolation ND7Treg sample revealed unique TCR transcript sequences 








4.1 NPT phenotypic changes 
 NPT was previously shown to eliminate 4T1 breast cancer tumors as well as N1-
S1 rat liver tumors to induce a vaccine effect suggesting immunotherapeutic potential. 
Unlike other immunotherapeutic agents, NPT actively kills cancer cells and stimulates the 
host’s immune system.  It was  shown in the 4T1-luc model (92), as others have reported 
in other cancer models (98), that NPT induces the release of damage-associated 
molecular patterns (DAMPs) and activates dendritic cells ex vivo and in vivo. Data 
supports the role of NPT as a non-drug immunogenic cell death inducer. Given that 
immunosuppression in the TME is the bane of immunotherapy, I was interested to 
determine more specifically the mechanisms by which NPT breaks this barrier to promote 
host-induced immunity in a predominantly immunosuppressive TME in mouse 4T1-luc 
breast cancer. 
  I have shown in this study that NPT reduces the local and systemic tumor 
immunosuppressive burden by reducing activated Tregs, TAMs and MDSCs in the tumor 
and other tissues (Fig. 26). While it was shown  previously that NPT induces apoptosis 
in liver cancer tissue (99), the cell types that underwent caspase-mediated cell death were 
not defined. Here I show that Tregs (in the dLN) and TAMs (in both, the tumor and dLN), 
but not conv T-cells, are among the apoptotic cell population most adversely impacted by 
NPT. These findings contrast with those seen in radiotherapy treatment, which was 





Tregs in the TME (90). Although  it was previously shown that a successful local NPT 
reduces the number of Tregs and MDSCs (92), this is the first study to investigate how 
NPT alters the phenotypic and functional dynamics of local Tregs. 
4.2 NPT-induced differential changes in T cell subset frequencies 
 When evaluating the differences among T cell subsets, I found that NPT reduced 
intratumoral Tregs more aggressively than conventional CD4 TILs. To better understand 
this observation, I evaluated the Tconv/Treg ratio and found it significantly elevated in all 
the tissues post-treatment, suggesting that the CD4 cells shifted away from a suppressive 
Treg population and towards an effector T cell profile. Interestingly in the dLN, Tregs were 
found to be more prone to apoptotic changes post-treatment when compared to their CD8 
and CD4 T effector counterparts. A study by Plaza-Servant et al. demonstrated that Tregs 
have an increased sensitivity to apoptosis in relation to Tconv (100). This sensitivity was 
correlated with a lower expression of c-FlipL, a member of the extrinsic apoptosis 
pathway, among Tregs when compared to Tconv. Among Tregs, the increased sensitivity 
to apoptosis was mostly restricted to activated CD44+CD62L- Tregs when compared to 
naïve CD44-CD62L+ Tregs (100). The lower c-FlipL expression in Tregs may be the 
reason why they are more vulnerable, than their Tconv counterparts, to apoptotic changes 
resulting from NPT. 
4.3 Reduction in Treg activation and function post-NPT 
 Since Tregs are critical in keeping the immune system from attacking self-antigens, 
a non-selective Treg depletion approach, such as using anti-CD25, results in 
autoimmunity (80). Treg depletion in Foxp3DTR-GFP mouse tumor models initially results 





is therefore critical to selectively deplete activated Tregs, or ideally tumor-specific Tregs 
in the TME. In order to find which subgroups of Tregs were most affected by NPT, I 
analyzed the expression of different Treg activation markers and found 4-1BB to be 
exclusively expressed among Foxp3+ CD4 Tregs in tumor-bearing mice, absent among 
other T cell subsets, and entirely absent in naïve mice T cells. Treg 4-1BB expression 
was also clearly and consistently downregulated post-treatment, making it an excellent 
marker to track the impact of NPT on the local and systemic Treg dynamics. 
 Overall, I found NPT shifted the Treg phenotypic dynamics from a predominantly 
activated (CD44+CD62L-) population with higher TGFβ and 4-1BB expression to a 
predominantly naïve (CD44-CD62L+) population with lower 4-1BB expression, which is 
consistent with a reduced functional suppressive capability. Studies have shown that in 
vivo depletion of 4-1BB+ Tregs inhibits tumor growth, and Tregs lacking 4-1BB have an 
impaired suppressive function (104).  
 Interestingly, I also observed a transient peak in both apoptotic and 4-1BB+ Tregs 
in the dLN at 4 hours post-treatment followed by their reduction in the following days, 
hinting that these Tregs may have a transient spike in activation and suppressive function 
before dying. Although apoptotic Tregs are described in literature as being more efficient 
at their suppressive function (105), a Treg suppression assay would be needed to confirm 
whether these apoptotic Tregs at 4 hours post-NPT truly have an increased functional 
capacity. Nevertheless, the elevation of 4-1BB+ Tregs lasts less than 24 hours after NPT. 
Considering DC activation observed at Day 2 post-NPT (92) and M1-polarization 
occurring at Day 3 post-treatment, these cells unlikely have a significant impact on the 





4.4 Activation of the antitumor immune branch 
 Studies on NPT have shown an increase in activated DCs and cytotoxic and 
memory T cells responsible for tumor clearance and antitumor immunity (92). These 
findings are concurrent with 100% rejection of the secondary tumor challenge following a 
successful treatment of the primary tumor with 100 ns NPT (92). In this current study I 
demonstrated a shift in both innate and adaptive immune branches from a pro-tumor to 
an antitumor profile. In the innate immune arm, I saw an immediate TAM apoptosis and 
a gradual MDSC reduction post-treatment, with a concomitant upregulation of antitumor 
activated CD86+ M1 TAMs. Blood MDSCs, which accurately reflect changes in the overall 
tumor burden (92), also demonstrated a gradual decrease post-treatment. Meanwhile in 
the adaptive immune branch, I observed a phenotypic and functional post-treatment 
decrease in Tregs followed by a gradual increase in resident memory CD8 T cells at days 
3 and 7. Thus, NPT encouraged coordinate host changes in both the lymphoid and 
myeloid immune systems to shift from an immunosuppressive to an immunostimulatory 































































































































































































































































4.5 Underlying mechanisms of differential changes in intratumoral immune cells 
 When comparing the impact of NPT on different immune cells in the TME, I found 
that while intratumoral Tregs swiftly decreased following NPT, they did not demonstrate 
significant post-treatment apoptosis as seen among dLN Tregs.  
 While I observed a rapid shift to apoptosis in intratumoral TAMs following NPT, I 
do not yet know why the treatment reduced intratumoral Tregs without similarly inducing 
their apoptosis in the TME. I speculate that such a rapid TIL depletion following NPT may 
have been the result of an immediate (possibly accidental) cell death mechanism that 
was no longer detected after 4 hours, an electro-expulsive force causing a massive TIL 
exodus, or an abrogation of tumor signaling factors, whether cell-contact dependent 
proteins or tissue-specific chemo-attractants, that had previously kept Tregs confined to 
the TME. 
 Co-culturing healthy dLN lymphocytes with in vitro pulsed 4T1-luc tumor cells 
demonstrated that Tregs heavily rely on a healthy tumor presence for their survival and 
that NPT has an antitumor impact on both the host immune cells as well as the TME. This 
finding confirms that NPT induces a dual specificity effect in cancer cell elimination and 
reprogramming the host’s immune system to participate in the antitumor effects through 
natural immunity in the 4T1-luc model. Future studies of the post-treatment changes in 
the TME-Treg signaling mechanism and local T cell trafficking patterns will help further to 
clarify these findings. Pulsing Tregs in vitro will reveal what direct impact NPT has on the 





4.6 Treg TCR clonality  
 Investigating the impact NPT may have on the Treg and Tconv TCR clonality in 
mice will help bring our studies closer to clinical trials. Our control studies on the blood of 
healthy individual donors indicated that human peripheral CD4+ Tregs are mostly 
polyclonal in nature.  
 A recent study on the Treg TCR in patient tumors suggested that tumors contain 
activated Tregs that proliferate in an antigen specific manner (61).  I speculate that the 
downregulation of the 4-1BB+ Tregs and shift from a predominantly activated to a 
predominantly naïve Treg population is a result of NPT-induced downregulation of the 
accumulated tumor antigen-specific Tregs. An investigation of the Treg TCR clonality 
before and after treatment will further reveal whether NPT reduces clonally expanded 
antigen-specific Tregs. Investigating for changes in the CD8 T cell TCR clonality in 
parallel with the above study will further demonstrate whether a rise in antigen-specific 









 NPT confers local and systemic benefits by reducing the immunosuppressive 
burden and eliciting protective antitumor immunity. Therefore, it is critical to understand 
how the treatment impacts Tregs, a key player of the immunosuppressive barrier, and 
how it tips the Treg/Teff axis from a tumorigenic to a tumor-eliminative response. 
  These studies enhance the concept that NPT is a potent TME modifier that 
differentially affects immune cells in the tumor. NPT diminished local and systemic Treg 
frequencies, their expression of activation markers and their functional suppressive 
capacity. The treatment also reduced local TAMs and systemic MDSCs. Tregs in the dLN 
and intratumoral TAMs were further found to undergo a rapid increase in apoptosis post-
treatment. Along with the diminution of immunosuppressive cells, NPT also preserved 
CD4 and CD8 Tconv, increased the CD8 Trm frequency, and promoted the M1-
polarization of surviving TAMs, indicating the initiation of antitumor immunity post-NPT. 
 These discoveries, along with our previous work, suggest that NPT is a novel non-
drug ICD inducer and a promising in situ vaccination approach to reduce the risk of 
metastatic disease, the major cause of breast cancer death. Other local cancer therapies, 
such as radiotherapy, require several immune modulators to ablate tumors and create a 
long-term protective effect. In contrast, a single nanopulse treatment has been 
demonstrated to elicit effective antitumor immunity. These findings make NPT a promising 
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